BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006;355:11-20. [DOI: 10.1056/nejmoa055531] [Cited by in Crossref: 3506] [Cited by in F6Publishing: 1609] [Article Influence: 233.7] [Reference Citation Analysis]
Number Citing Articles
1 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/thenocoligist.2010-0387] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 van der Horst S, Weijs TJ, Ruurda JP, Haj Mohammad N, Mook S, Brosens LAA, van Hillegersberg R. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. J Thorac Dis 2017;9:S834-42. [PMID: 28815081 DOI: 10.21037/jtd.2017.03.151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
3 Schuhmacher C, Novotny A, Ott K, Feith M, Siewert JR. [Lymphadenectomy with tumors of the upper gastrointestinal tract]. Chirurg 2007;78:203-6, 208-12, 214-6. [PMID: 17333037 DOI: 10.1007/s00104-007-1307-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
4 Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res 2016;22:6228-35. [PMID: 27654712 DOI: 10.1158/1078-0432.CCR-15-2468] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
5 Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, Henke M, Hopt UT, Hoeppner J. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg 2013;17:1193-201. [PMID: 23636882 DOI: 10.1007/s11605-013-2212-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
6 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
7 Tang L, Duan R, Zhong YJ, Firestone RA, Hong YP, Li JG, Xin YC, Wu HL, Li Y. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity. Mol Cancer 2014;13:44. [PMID: 24588871 DOI: 10.1186/1476-4598-13-44] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M. Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer 2017;20:448-56. [PMID: 27586236 DOI: 10.1007/s10120-016-0637-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, Park SR, Yook JH, Oh ST, Yoo MW, Kim BS. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. Gastric Cancer. 2017;20:182-189. [PMID: 26661592 DOI: 10.1007/s10120-015-0580-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, Smith AD, Urquhart G, Bielawski J, Finnegan M, Petty R. Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer 2015;15:762. [PMID: 26493335 DOI: 10.1186/s12885-015-1718-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
11 Monti M, Morgagni P, Nanni O, Framarini M, Saragoni L, Marrelli D, Roviello F, Petrioli R, Fumagalli Romario U, Rimassa L, Bozzarelli S, Donini A, Graziosi L, De Angelis V, De Manzoni G, Bencivenga M, Mengardo V, Parma E, Milandri C, Mura G, Signorini A, Baiocchi G, Molfino S, Sgroi G, Steccanella F, Rausei S, Proserpio I, Viganò J, Brugnatelli S, Rinnovati A, Santi S, Ercolani G, Foca F, Valmorri L, Amadori D, Frassineti GL. Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers (Basel) 2020;12:E2790. [PMID: 33003302 DOI: 10.3390/cancers12102790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kobayashi D, Ishigure K, Mochizuki Y, Nakayama H, Sakai M, Ito S, Kojima H, Kajikawa M, Ando M, Kodera Y. Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301). Gastric Cancer 2017;20:718-27. [PMID: 27885538 DOI: 10.1007/s10120-016-0668-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
13 Nadauld L, Regan JF, Miotke L, Pai RK, Longacre TA, Kwok SS, Saxonov S, Ford JM, Ji HP. Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Transl Med (Sunnyvale) 2012;2:1000107. [PMID: 23682346 DOI: 10.4172/2161-1025.1000107] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
14 Zhang PF, Sheng LL, Wang G, Tian M, Zhu LY, Zhang R, Zhang J, Zhu JS. miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget. 2016;7:35284-35292. [PMID: 27167197 DOI: 10.18632/oncotarget.9169] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
15 Li Z, Li S, Ying X, Zhang L, Shan F, Jia Y, Ji J. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer 2020;23:540-9. [PMID: 32072387 DOI: 10.1007/s10120-019-01027-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
16 Roh CK, Choi YY, Choi S, Seo WJ, Cho M, Jang E, Son T, Kim HI, Kim H, Hyung WJ, Huh YM, Noh SH, Cheong JH. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Med J 2019;60:132-9. [PMID: 30666834 DOI: 10.3349/ymj.2019.60.2.132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
17 Botha AJ, Odendaal W, Patel V, Watcyn-Jones T, Mahadeva U, Chang F, Deere H. Total adventitial resection of the cardia: 'optimal local resection' for tumours of the oesophagogastric junction. Ann R Coll Surg Engl 2011;93:608-14. [PMID: 22041237 DOI: 10.1308/003588411X13165261994111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chen D, Jiang B, Xing J, Liu M, Cui M, Liu Y, Wang Z, Chen L, Yang H, Zhang C, Yao Z, Zhang N, Ji J, Qu H, Su X. Validation of the memorial Sloan-Kettering Cancer Center nomogram to predict disease-specific survival after R0 resection in a Chinese gastric cancer population. PLoS One 2013;8:e76041. [PMID: 24146811 DOI: 10.1371/journal.pone.0076041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
19 Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y, Zhang C. Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Oncol Lett 2015;9:999-1005. [PMID: 25624920 DOI: 10.3892/ol.2014.2793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Kung CH, Song H, Ye W, Nilsson M, Johansson J, Rouvelas I, Irino T, Lundell L, Tsai JA, Lindblad M. Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden. Chin J Cancer Res 2017;29:313-22. [PMID: 28947863 DOI: 10.21147/j.issn.1000-9604.2017.04.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Song XH, Liu K, Yang SJ, Zhang WH, Chen XL, Zhao LY, Chen XZ, Yang K, Zhou ZG, Hu JK. Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Front Oncol 2020;10:1432. [PMID: 33014781 DOI: 10.3389/fonc.2020.01432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Yokota T, Machida N, Yamazaki K, Fukutomi A, Onozawa Y, Terashima M, Uesaka K, Yasui H. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 2018;21:338-344. [PMID: 28577228 DOI: 10.1007/s10120-017-0730-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
23 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
24 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Shang C, Sun L, Zhang J, Zhao B, Chen X, Xu H, Huang B. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget. 2017;8:15393-15398. [PMID: 28146436 DOI: 10.18632/oncotarget.14871] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
26 Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14. [PMID: 25589897 DOI: 10.4103/1477-3163.146506] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 18.0] [Reference Citation Analysis]
27 Miyawaki Y, Sato H, Oya S, Sugita H, Hirano Y, Sakuramoto S, Okamotom K, Yamaguchim S, Koyama I. Clinical impact of abdominal versus mediastinal metastases as a prognostic factor for poor outcomes following esophageal cancer surgery: a retrospective study. BMC Cancer 2021;21:725. [PMID: 34162359 DOI: 10.1186/s12885-021-08484-2] [Reference Citation Analysis]
28 Wang C, Fu X, Cai X, Wu X, Hu X, Fan M, Xiang J, Zhang Y, Chen H, Jiang G, Zhao K. High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. Onco Targets Ther 2016;9:117-22. [PMID: 26766917 DOI: 10.2147/OTT.S89592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol 2014;73:1047-54. [PMID: 24652604 DOI: 10.1007/s00280-014-2440-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
30 Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, Liu BY, Gu QL. Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett 2013;5:896-902. [PMID: 23425977 DOI: 10.3892/ol.2012.1092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
31 Liu Y, Zhao G, Xu Y, Zhang T, Chen Z, Yan G, Tu W, Hu Y, Chen Y, He X, Li X, Chen H, Yao S, Hu Z, Chen X, Chen T. Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma. Am J Clin Oncol 2018;41:619-25. [PMID: 28263232 DOI: 10.1097/COC.0000000000000373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Zhi Y, Lin Z, Ma J, Mou W, Chen X. Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node. Technol Cancer Res Treat 2020;19:1533033820959400. [PMID: 33148125 DOI: 10.1177/1533033820959400] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Khorfan R, Schlick CJR, Yang AD, Odell DD, Bentrem DJ, Merkow RP. Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. J Gastrointest Surg 2020;24:243-52. [PMID: 31749097 DOI: 10.1007/s11605-019-04410-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rawicz-Pruszyński K, Ciseł B, Mlak R, Mielko J, Skórzewska M, Kwietniewska M, Pikuła A, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Cancers (Basel) 2019;11:E1914. [PMID: 31805755 DOI: 10.3390/cancers11121914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
35 Zhu K, Jin H, Li Z, Gao Y, Zhang Q, Liu X, Yu J. The Prognostic Value of Lymph Node Ratio after Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Adenocarcinoma. J Gastric Cancer 2021;21:49-62. [PMID: 33854813 DOI: 10.5230/jgc.2021.21.e5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 van den Berg JW, Tabrett K, Cheong E. Paravertebral catheter analgesia for minimally invasive Ivor Lewis oesophagectomy. J Thorac Dis 2019;11:S786-93. [PMID: 31080659 DOI: 10.21037/jtd.2019.03.47] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Pecqueux M, Fritzmann J, Adamu M, Thorlund K, Kahlert C, Reißfelder C, Weitz J, Rahbari NN. Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. Oncotarget 2015;6:35564-78. [PMID: 26384352 DOI: 10.18632/oncotarget.5595] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
38 Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. [PMID: 21617522 DOI: 10.1097/PAI.0b013e31821c821c] [Cited by in Crossref: 80] [Cited by in F6Publishing: 48] [Article Influence: 8.9] [Reference Citation Analysis]
39 Huang ZN, Ma Y, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching. Surg Endosc 2021. [PMID: 34085095 DOI: 10.1007/s00464-021-08430-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 He Q, Ma L, Li Y, Li G. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. BMC Gastroenterol. 2016;16:8. [PMID: 26782354 DOI: 10.1186/s12876-016-0422-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
41 Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, Jia Y, Xue K, Miao R, Li Z, Ji J. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS One 2018;13:e0189294. [PMID: 29370182 DOI: 10.1371/journal.pone.0189294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
42 Lamb P, Sivashanmugam T, White M, Irving M, Wayman J, Raimes S. Gastric cancer surgery--a balance of risk and radicality. Ann R Coll Surg Engl 2008;90:235-42. [PMID: 18430340 DOI: 10.1308/003588408X261546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
43 Javle M, Hsueh CT. Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010;3:11. [PMID: 20331897 DOI: 10.1186/1756-8722-3-11] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37. [PMID: 26238344 DOI: 10.1186/s12904-015-0034-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
45 Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12. [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z] [Cited by in Crossref: 158] [Cited by in F6Publishing: 150] [Article Influence: 19.8] [Reference Citation Analysis]
46 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R, Taniguchi H, Sano T, Sasako M, Fukuda H. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer. 2015;18:597-604. [PMID: 24968818 DOI: 10.1007/s10120-014-0401-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
48 Farkhondeh T, Pourbagher-Shahri AM, Azimi-Nezhad M, Forouzanfar F, Brockmueller A, Ashrafizadeh M, Talebi M, Shakibaei M, Samarghandian S. Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. Molecules 2021;26:3157. [PMID: 34070502 DOI: 10.3390/molecules26113157] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Wang ZC, Wang C, Ding Y, Ji Y, Zeng MS, Rao SX. CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. Diagn Interv Radiol 2017;23:257-62. [PMID: 28703101 DOI: 10.5152/dir.2017.16517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 McCall MD, Graham PJ, Bathe OF. Quality of life: A critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol 2016; 22(3): 1101-1113 [PMID: 26811650 DOI: 10.3748/wjg.v22.i3.1101] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
51 Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, Di Carlo V. Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg 2013;17:488-93. [PMID: 23132627 DOI: 10.1007/s11605-012-2063-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
52 Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21. [PMID: 32512697 DOI: 10.3390/ijms21114012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 37.0] [Reference Citation Analysis]
53 Metzger R, Warnecke-Eberz U, Alakus H, Kütting F, Brabender J, Vallböhmer D, Grimminger PP, Mönig SP, Drebber U, Hölscher AH. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16:26-34; discussion 34. [PMID: 21956434 DOI: 10.1007/s11605-011-1700-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
54 Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med 2020;9:5731-45. [PMID: 32583567 DOI: 10.1002/cam4.3224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
55 Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330-335. [PMID: 23523184 DOI: 10.1016/j.ijrobp.2013.02.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
56 Lin GS, Huang XY, Lu J, Wu D, Zheng HL, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Lin GT, Huang ZN, Lin JL, Huang CM. A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients. Surg Endosc 2021. [PMID: 34076769 DOI: 10.1007/s00464-021-08461-7] [Reference Citation Analysis]
57 Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, Mariette C. Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg. 2012;36:346-354. [PMID: 22102091 DOI: 10.1007/s00268-011-1351-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
58 Lagarde SM, Anderegg MCJ, Gisbertz SS, Meijer SL, Hulshof MCCM, Bergman JJGHM, van Laarhoven HWM, van Berge Henegouwen MI. Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. J Thorac Dis 2018;10:1511-21. [PMID: 29707301 DOI: 10.21037/jtd.2018.02.81] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Powell AGMT, Wheat J, Patel N, Chan D, Foliaki A, Roberts SA, Lewis WG; South-East Wales Oesophagogastric Cancer Collaborative. Value of individual surgeon performance metrics as quality assurance measures in oesophagogastric cancer surgery. BJS Open 2020;4:91-100. [PMID: 32011808 DOI: 10.1002/bjs5.50230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
60 Guan Z, Song B, Liu F, Sun D, Wang K, Qu H. TGF-β induces HLA-G expression through inhibiting miR-152 in gastric cancer cells. J Biomed Sci 2015;22:107. [PMID: 26627200 DOI: 10.1186/s12929-015-0177-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
61 Manzini G, Henne-Bruns D, Kremer M. Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials. BMJ Open Gastroenterol. 2017;4:e000138. [PMID: 29177062 DOI: 10.1136/bmjgast-2017-000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Hoibian S, Giovannini M, Autret A, Pesenti C, Bories E, Ratone JP, Dahel Y, Dermeche S, Meillat H, Guiramand J, Caillol F. Preoperative EUS evaluation of the response to neoadjuvant therapy for gastric and esophagogastric junction cancer is correlated with survival: A single retrospective study of 97 patients. Endosc Ultrasound 2021;10:103-10. [PMID: 33666179 DOI: 10.4103/EUS-D-20-00073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Nakauchi M, Vos E, Janjigian YY, Ku GY, Schattner MA, Nishimura M, Gonen M, Coit DG, Strong VE. Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Ann Surg Oncol 2021;28:3532-44. [PMID: 33709174 DOI: 10.1245/s10434-021-09798-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Felipe AV, Oliveira J, Moraes AA, França JP, Silva TD, Forones NM. Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline. Asian Pac J Cancer Prev 2018;19:1237-42. [PMID: 29801407 DOI: 10.22034/APJCP.2018.19.5.1237] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Uggeri F, Ripamonti L, Pinotti E, Scotti MA, Famularo S, Garancini M, Gianotti L, Braga M, Romano F. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer? World J Clin Oncol 2020; 11(7): 477-494 [PMID: 32821653 DOI: 10.5306/wjco.v11.i7.477] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Schmidt T, Sisic L, Sterzing F, Haag GM, Kunzmann R, Grenacher L, Weichert W, Jäger D, Büchler MW, Ott K. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)]. Chirurg 2015;86:955-62. [PMID: 25715974 DOI: 10.1007/s00104-014-2971-z] [Reference Citation Analysis]
67 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 2021;39:2903-13. [PMID: 34133211 DOI: 10.1200/JCO.20.02914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ruan T, Liu W, Tao K, Wu C. A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer. Onco Targets Ther 2020;13:1797-807. [PMID: 32184615 DOI: 10.2147/OTT.S239336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
70 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
71 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]
72 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
73 Zhou ML, Wang L, Wang JZ, Yang W, Hu R, Li GC, Sheng WQ, Zhang Z. Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget 2016;7:64757-65. [PMID: 27588465 DOI: 10.18632/oncotarget.11665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
74 Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161 [PMID: 23599641 DOI: 10.3748/wjg.v19.i14.2154] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
75 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
76 Sun Y, Yang L, Wang C, Zhao D, Cai J, Li W, Zhang W, Huang J, Zhou A. Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection. Oncotarget 2017;8:75186-94. [PMID: 29088856 DOI: 10.18632/oncotarget.20660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Özer İ, Bostancı EB, Ulaş M, Özoğul Y, Akoğlu M. Changing Trends in Gastric Cancer Surgery. Balkan Med J 2017;34:10-20. [PMID: 28251018 DOI: 10.4274/balkanmedj.2015.1461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-393. [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
79 Yi JH, Do IG, Jang J, Kim ST, Kim KM, Park SH, Park JO, Park YS, Lim HY, Kang WK. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep. 2014;4:7592. [PMID: 25534230 DOI: 10.1038/srep07592] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
80 Li Z, Shan F, Ying X, Zhang L, Ren H, Li S, Jia Y, Miao R, Xue K, Li Z, Wang Y, Yan C, Zhang Y, Pang F, Ji J. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial. BMJ Open 2018;8:e021633. [PMID: 30099396 DOI: 10.1136/bmjopen-2018-021633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
81 Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res 2017;23:7543-9. [PMID: 28972045 DOI: 10.1158/1078-0432.CCR-16-3142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 2018;21:74-83. [PMID: 28643144 DOI: 10.1007/s10120-017-0743-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
83 de Pascale S, Parise P, Valmasoni M, Weindelmayer J, Terraneo F, Cella CA, Giacopuzzi S, Cossu A, Massaron S, Elmore U, Merigliano S, Fumagalli Romario U, On Behalf Of The Italian Society For The Study Of Esophageal Diseases Sisme. Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. Cancers (Basel) 2021;13:666. [PMID: 33562316 DOI: 10.3390/cancers13040666] [Reference Citation Analysis]
84 Saito T, Kurokawa Y, Takiguchi S, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Mori M, Doki Y. Accuracy of multidetector-row CT in diagnosing lymph node metastasis in patients with gastric cancer. Eur Radiol. 2015;25:368-374. [PMID: 25097136 DOI: 10.1007/s00330-014-3373-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
85 Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727 [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
86 Xiang M, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer 2020;23:175-83. [PMID: 31230228 DOI: 10.1007/s10120-019-00980-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
88 Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C. Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments. Cancers (Basel) 2019;12:E20. [PMID: 31861604 DOI: 10.3390/cancers12010020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Ni X, Yang J, Li M. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett. 2012;324:179-185. [PMID: 22617626 DOI: 10.1016/j.canlet.2012.05.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
90 Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2013;Sep 1; Epub ahead of print. [PMID: 23996162 DOI: 10.1007/s10120-013-0296-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
91 Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, Casciola L. Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc 2008;22:2753-60. [PMID: 18813994 DOI: 10.1007/s00464-008-0129-0] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
92 Ren F, Li S, Zhang Y, Zhao Z, Wang H, Cui Y, Wang M. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol 2019;14:84. [PMID: 31118042 DOI: 10.1186/s13014-019-1294-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
93 Glatz T, Kulemann B, Marjanovic G, Bregenzer S, Makowiec F, Hoeppner J. Postoperative fluid overload is a risk factor for adverse surgical outcome in patients undergoing esophagectomy for esophageal cancer: a retrospective study in 335 patients. BMC Surg. 2017;17:6. [PMID: 28086855 DOI: 10.1186/s12893-016-0203-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
94 Blank S, Nienhüser H, Dreikhausen L, Sisic L, Heger U, Ott K, Schmidt T. Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget 2017;8:47518-32. [PMID: 28537901 DOI: 10.18632/oncotarget.17671] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
95 Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology 2016;5:e1100789. [PMID: 27467911 DOI: 10.1080/2162402X.2015.1100789] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
96 Okabayashi K, Fujita T, Miyazaki J, Okada T, Iwata T, Hirao N, Noji S, Tsukamoto N, Goshima N, Hasegawa H, Takeuchi H, Ueda M, Kitagawa Y, Kawakami Y. Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. Cancer Sci 2012;103:1617-24. [PMID: 22676270 DOI: 10.1111/j.1349-7006.2012.02355.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
97 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Martin-Romano P, Solans BP, Cano D, Subtil JC, Chopitea A, Arbea L, Lozano MD, Castanon E, Baraibar I, Salas D, Hernandez-Lizoain JL, Trocóniz IF, Rodriguez J. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS One 2019;14:e0215970. [PMID: 31071108 DOI: 10.1371/journal.pone.0215970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wang H, Wang C, Tian W, Yao Y. The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. Oncotarget 2017;8:72157-66. [PMID: 29069776 DOI: 10.18632/oncotarget.20048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
100 Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol 2014; 20(7): 1650-1656 [PMID: 24587644 DOI: 10.3748/wjg.v20.i7.1650] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
101 Futsukaichi T, Etoh T, Nakajima K, Daa T, Shiroshita H, Shiraishi N, Kitano S, Inomata M. Decreased expression of Bauhinia purpurea lectin is a predictor of gastric cancer recurrence. Surg Today 2015;45:1299-306. [PMID: 25753302 DOI: 10.1007/s00595-015-1127-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
102 Jácome AA, Coutinho AK, Lima EM, Andrade AC, Santos JSD. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol 2016; 22(3): 1160-1171 [PMID: 26811654 DOI: 10.3748/wjg.v22.i3.1160] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
103 Kim SG, Hwang SH. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. World J Surg Oncol 2016;14:102. [PMID: 27039375 DOI: 10.1186/s12957-016-0845-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
104 Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, Tesei A. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. Oncotarget. 2016;7:18424-18439. [PMID: 26919099 DOI: 10.18632/oncotarget.7575] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
105 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
106 Boniface MM, Wani SB, Schefter TE, Koo PJ, Meguid C, Leong S, Kaplan JB, Wingrove LJ, McCarter MD. Multidisciplinary management for esophageal and gastric cancer. Cancer Manag Res. 2016;8:39-44. [PMID: 27217796 DOI: 10.2147/CMAR.S101169] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
107 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
108 Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011;11:266. [PMID: 21702914 DOI: 10.1186/1471-2407-11-266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
109 Hu Y, Zaydfudim VM. Quality of Life After Curative Resection for Gastric Cancer: Survey Metrics and Implications of Surgical Technique. J Surg Res 2020;251:168-79. [PMID: 32151826 DOI: 10.1016/j.jss.2020.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
110 Li SX, Seo SH, Choi YY, Nakagawa M, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH. Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. BMC Cancer 2016;16:29. [PMID: 26786480 DOI: 10.1186/s12885-016-2066-y] [Reference Citation Analysis]
111 Hung HY, Yeh CY, Changchien CR, Chen JS, Fan CW, Tang R, Hsieh PS, Tasi WS, You YT, You JF, Wang JY, Chiang JM. Surgical resection of locally advanced primary transverse colon cancer--not a worse outcome in stage II tumor. Int J Colorectal Dis 2011;26:859-65. [PMID: 21279365 DOI: 10.1007/s00384-011-1146-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Leibl BJ, Vitz S, Schäfer W, Alfrink M, Gschwendtner A, Grabenbauer GG. Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery : early results and toxicity. Strahlenther Onkol 2011;187:231-7. [PMID: 21437768 DOI: 10.1007/s00066-011-2171-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
113 Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med 2015;7:273ra14. [PMID: 25653220 DOI: 10.1126/scitranslmed.3009951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
114 Schumann M, Schulz H, Hackney AC, Bloch W. Feasibility of high-intensity interval training with hyperoxia vs. intermittent hyperoxia and hypoxia in cancer patients undergoing chemotherapy - Study protocol of a randomized controlled trial. Contemp Clin Trials Commun 2017;8:213-7. [PMID: 29696212 DOI: 10.1016/j.conctc.2017.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Kundel Y, Purim O, Idelevich E, Lavrenkov K, Man S, Kovel S, Karminsky N, Pfeffer RM, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study. Radiat Oncol 2011;6:127. [PMID: 21958692 DOI: 10.1186/1748-717X-6-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Power R, Lowery MA, Reynolds JV, Dunne MR. The Cancer-Immune Set Point in Oesophageal Cancer. Front Oncol. 2020;10:891. [PMID: 32582553 DOI: 10.3389/fonc.2020.00891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
117 Xu W, Ma Q, Wang L, He C, Lu S, Ni Z, Hua Z, Zhu Z, Yang Z, Zheng Y, Feng R, Yan C, Li C, Yao X, Chen M, Liu W, Yan M, Zhu Z. Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative Chemotherapy. Front Oncol 2021;11:607640. [PMID: 33937020 DOI: 10.3389/fonc.2021.607640] [Reference Citation Analysis]
118 De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer 2015;113:1305-12. [PMID: 26484410 DOI: 10.1038/bjc.2015.342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
119 Vita FD, Martino ND, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014; 20(40): 14537-14558 [PMID: 25356019 DOI: 10.3748/wjg.v20.i40.14537] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
120 Kim TS, da Silva E, Coit DG, Tang LH. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. Am J Surg Pathol 2019;43:851-60. [PMID: 30969179 DOI: 10.1097/PAS.0000000000001253] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
121 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
122 Song F, Wang H, Wang Y. Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer. Oncotarget 2017;8:90050-60. [PMID: 29163810 DOI: 10.18632/oncotarget.21376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
123 Wang WH, Chen SK, Huang HC, Juan HF. Proteomic Analysis Reveals That Metformin Suppresses PSMD2, STIP1, and CAP1 for Preventing Gastric Cancer AGS Cell Proliferation and Migration. ACS Omega 2021;6:14208-19. [PMID: 34124444 DOI: 10.1021/acsomega.1c00894] [Reference Citation Analysis]
124 Zhao Q, Li Y, Tan B, Fan L, Yang P, Tian Y, Cheng JQ. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. PLoS ONE 2015;10:e0132746. [DOI: 10.1371/journal.pone.0132746] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
125 Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, Yasufuku I, Okumura Y, Tsujiura M, Ida S, Nunobe S, Ohashi M, Sano T, Yamaguchi T. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer 2018;21:703-9. [PMID: 29188456 DOI: 10.1007/s10120-017-0781-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
126 Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, Pugliese R, Ferrari G. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8:1018-1025. [PMID: 29299362 DOI: 10.21037/jgo.2017.08.13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
127 Javidfar J, Speicher PJ, Hartwig MG, D'Amico TA, Berry MF. Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. Ann Thorac Surg 2016;101:1060-7. [PMID: 26576752 DOI: 10.1016/j.athoracsur.2015.09.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
128 Baiocchi G, Portolani N, Gheza F, Giulini SM. Collagen-based biological glue after Appleby operation for advanced gastric cancer. World J Gastroenterol 2011; 17(35): 4044-4047 [PMID: 22046095 DOI: 10.3748/wjg.v17.i35.4044] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
129 Bibby BA, Reynolds JV, Maher SG. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS One 2015;10:e0134180. [PMID: 26221725 DOI: 10.1371/journal.pone.0134180] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
130 Slotta-Huspenina J, Berg D, Bauer K, Wolff C, Malinowsky K, Bauer L, Drecoll E, Bettstetter M, Feith M, Walch A, Höfler H, Becker KF, Langer R. Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas. PLoS One 2012;7:e41420. [PMID: 22911792 DOI: 10.1371/journal.pone.0041420] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
131 Koumarianou A, Krivan S, Machairas N, Ntavatzikos A, Pantazis N, Schizas D, Martikos G, Kampoli K, Misiakos EP, Patapis P, Liakakos T. Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Ann Gastroenterol 2019;32:99-106. [PMID: 30598599 DOI: 10.20524/aog.2018.0320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Knight WRC, Yip C, Wulaningsih W, Jacques A, Griffin N, Zylstra J, Van Hemelrijck M, Maisey N, Gaya A, Baker CR, Kelly M, Gossage JA, Lagergren J, Landau D, Goh V, Davies AR, Ngan S, Qureshi A, Deere H, Green M, Chang F, Mahadeva U, Gill-Barman B, George S, Dunn J, Zeki S, Meenan J, Hynes O, Tham G, Iezzi C; Guy's and St Thomas' Oesophago‐Gastric Research Group. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open 2019;3:767-76. [PMID: 31832583 DOI: 10.1002/bjs5.50211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Ishida K, Ito C, Ohmori Y, Kume K, Sato KA, Koizumi Y, Konta A, Iwaya T, Nukatsuka M, Kobunai T, Takechi T, Nishizuka SS. Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. Sci Rep 2017;7:2262. [PMID: 28536445 DOI: 10.1038/s41598-017-02548-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
135 Roberts G, Hardwick R, Fitzgerald RC. Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. Transl Gastroenterol Hepatol 2017;2:21. [PMID: 28447056 DOI: 10.21037/tgh.2017.03.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Wong J. Impact of pathologic tumor response in the treatment of gastric cancer. Transl Gastroenterol Hepatol 2016;1:71. [PMID: 28138637 DOI: 10.21037/tgh.2016.09.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
137 Schauer M, Knoefel WT, Friess H, Theisen J. The amount of neoadjuvant chemotherapy for Barrett's carcinoma does not correlate with long-term survival. J Gastrointest Surg 2011;15:1750-5. [PMID: 21811882 DOI: 10.1007/s11605-011-1623-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Polat E, Duman U, Duman M, Derya Peker K, Akyuz C, Fatih Yasar N, Uzun O, Akbulut S, Birol Bostanci E, Yol S. Preoperative serum tumor marker levels in gastric cancer. Pak J Med Sci 2014;30:145-9. [PMID: 24639849 DOI: 10.12669/pjms.301.3968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
140 何若冰, 陈俊强. 胃癌新辅助化疗的研究进展. 世界华人消化杂志 2009; 17(12): 1207-1211 [DOI: 10.11569/wcjd.v17.i12.1207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
141 Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, Cameron D. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56-64. [PMID: 27777129 DOI: 10.1016/j.cct.2016.10.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 15.8] [Reference Citation Analysis]
142 Tharian B, Tsiopoulos F, George N, Pietro SD, Attili F, Larghi A. Endoscopic ultrasound fine needle aspiration: Technique and applications in clinical practice. World J Gastrointest Endosc 2012; 4(12): 532-544 [PMID: 23293723 DOI: 10.4253/wjge.v4.i12.532] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
143 Liao YY, Peng NF, Long D, Yu PC, Zhang S, Zhong JH, Li LQ. Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg. 2017;17:14. [PMID: 28193210 DOI: 10.1186/s12893-017-0215-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
144 Wong C, Law S. Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis 2017;9:S773-80. [PMID: 28815073 DOI: 10.21037/jtd.2017.04.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
145 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434- 011-1631-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol 2021;28:2246-56. [PMID: 33000372 DOI: 10.1245/s10434-020-09149-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
147 Schröder W, Lambertz R, van Hillegesberger R, Bruns C. [Differentiated surgical approach for adenocarcinoma of the gastroesophageal junction]. Chirurg 2017;88:1010-6. [PMID: 29098306 DOI: 10.1007/s00104-017-0544-7] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Toxopeus E, van der Schaaf M, van Lanschot J, Lagergren J, Lagergren P, van der Gaast A, Wijnhoven B. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). Ann Surg Oncol. 2018;25:2441-2448. [PMID: 29948420 DOI: 10.1245/s10434-018-6554-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
149 Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54 [PMID: 21160774 DOI: 10.4251/wjgo.v1.i1.47] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
150 Dai D, Zhao X, Li X, Shu Y, Shen B, Chen X, Chen D, Wang D. Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. Front Oncol 2019;9:1452. [PMID: 31970085 DOI: 10.3389/fonc.2019.01452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
151 Fontana E, Sclafani F, Cunningham D. Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol 2014;35:253-62. [PMID: 25538401 DOI: 10.4103/0971-5851.144985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
152 Lourenço BN, Springer NL, Ferreira D, Oliveira C, Granja PL, Fischbach C. CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. Integr Biol (Camb) 2018;10:145-58. [PMID: 29450424 DOI: 10.1039/c7ib00179g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
153 Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085-1093. [PMID: 21229262 DOI: 10.1007/s00432-010-0972-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
154 Natori A, Chan BA, Sim HW, Ma L, Yokom DW, Chen E, Liu G, Darling G, Swallow C, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox J, Elimova E, Jang RW. Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer. Curr Oncol 2018;25:366-70. [PMID: 30607110 DOI: 10.3747/co.25.4208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
155 Stein A, Rüssel J, Peinert S, Arnold D. The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol 2010;2:389-98. [PMID: 21789150 DOI: 10.1177/1758834010375095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, Broeckaert MAM, Anagnostou V, Adleff V, Bruhm DC, Canzoniero JV, Fiksel J, Nordsmark M, Warmerdam FARM, Verheul HMW, van Spronsen DJ, Beerepoot LV, Geenen MM, Portielje JEA, Jansen EPM, van Sandick J, Meershoek-Klein Kranenbarg E, van Laarhoven HWM, van der Peet DL, van de Velde CJH, Verheij M, Fijneman R, Scharpf RB, Meijer GA, Cats A, Velculescu VE. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun 2020;11:525. [PMID: 31988276 DOI: 10.1038/s41467-020-14310-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
157 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
158 Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012;215:643-51. [PMID: 23084493 DOI: 10.1016/j.jamcollsurg.2012.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
159 Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, Haruki T, Hamamoto Y, Shiomi T, Nakabayashi M. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer. 2010;13:177-185. [PMID: 20820987 DOI: 10.1007/s10120-010-0558-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
160 O'Sullivan KE, Hurley ET, Hurley JP. Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterol Res Pract 2015;2015:518281. [PMID: 26246803 DOI: 10.1155/2015/518281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
161 Drummond RJ, Vass D, Wadhawan H, Craig CF, MacKay CK, Fullarton GM, Forshaw MJ. Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery. Ann R Coll Surg Engl 2018;100:515-9. [PMID: 29692190 DOI: 10.1308/rcsann.2018.0067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
162 Zuo J, Wang D, Shen H, Liu F, Han J, Zhang X. MicroRNA-153 inhibits tumor progression in esophageal squamous cell carcinoma by targeting SNAI1. Tumour Biol 2016. [PMID: 27739030 DOI: 10.1007/s13277-016-5427-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
163 Manzanedo I, Pereira F, Serrano Á, Pérez-Viejo E. Review of management and treatment of peritoneal metastases from gastric cancer origin. J Gastrointest Oncol 2021;12:S20-9. [PMID: 33968423 DOI: 10.21037/jgo-20-232] [Reference Citation Analysis]
164 Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53:1186-1195. [PMID: 29633013 DOI: 10.1007/s00535-018-1464-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
165 Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. 2018;50:518-529. [PMID: 28546521 DOI: 10.4143/crt.2017.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
166 Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011;1:573-579. [PMID: 22389872 DOI: 10.1158/2159-8290.cd-11-0175] [Cited by in Crossref: 86] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
167 Ben-David K, Tuttle R, Kukar M, Oxenberg J, Hochwald SN. Laparoscopic distal, subtotal gastrectomy for advanced gastric cancer. J Gastrointest Surg 2015;19:369-74. [PMID: 25338659 DOI: 10.1007/s11605-014-2666-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
168 Liakakos T, Roukos DH. Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 2008;22:1402-4. [PMID: 18365277 DOI: 10.1007/s00464-008-9890-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
169 Chen Y, Wu X, Liu C, Zhou Y. Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress. Cell Biochem Funct 2020;38:702-9. [PMID: 32283563 DOI: 10.1002/cbf.3537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
170 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
171 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco2009.26.6114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Cao Y, Xiong L, Deng S, Shen L, Li J, Wu K, Wang J, Tao K, Wang G, Cai K. The effect of perigastric lipolymphatic tissue grouping by surgeon on the number of pathologic sampled lymph nodes after radical gastrectomy. Medicine (Baltimore). 2018;97:e11411. [PMID: 29979440 DOI: 10.1097/md.0000000000011411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Yan J, Zheng Y, Zheng X, Liu Z, Liu W, Chen D, Dong X, Li K, Liu X, Chen G, Lu J, Chen J, Zhuo S, Li G. Real-time optical diagnosis of gastric cancer with serosal invasion using multiphoton imaging. Sci Rep 2016;6:31004. [PMID: 27499365 DOI: 10.1038/srep31004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
174 Jia Y, Dong B, Tang L, Liu Y, Du H, Yuan P, Wu A, Ji J. Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. Tumour Biol. 2012;33:1151-1158. [PMID: 22383294 DOI: 10.1007/s13277-012-0357-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
175 Pilar A, Gupta M, Ghosh Laskar S, Laskar S. Intraoperative radiotherapy: review of techniques and results. Ecancermedicalscience 2017;11:750. [PMID: 28717396 DOI: 10.3332/ecancer.2017.750] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
176 Spych M, Serbiak B, Rychter A, Jesien-Lewandowicz E, Gottwald L, Fijuth J. Post-operative radiochemotherapy in patients with gastric cancer: one department’s experience of 56 patients. Br J Radiol. 2011;84:457-463. [PMID: 21304007 DOI: 10.1259/bjr/25406515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
177 Ma F, Wang B, Xue L, Kang W, Li Y, Li W, Liu H, Ma S, Tian Y. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020;146:2135-2142. [PMID: 32306127 DOI: 10.1007/s00432-020-03214-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
178 Chang SC, Tang CM, Le PH, Kuo CJ, Chen TH, Wang SY, Chou WC, Chen TC, Yeh TS, Hsu JT. Impact of Pancreatic Resection on Survival in Locally Advanced Resectable Gastric Cancer. Cancers (Basel) 2021;13:1289. [PMID: 33799426 DOI: 10.3390/cancers13061289] [Reference Citation Analysis]
179 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
180 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 25] [Article Influence: 12.7] [Reference Citation Analysis]
181 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
182 Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, Ema A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Koizumi W, Watanabe M, Yamashita K. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer. 2019;22:598-606. [PMID: 30284080 DOI: 10.1007/s10120-018-0884-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
183 Crane SJ, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ. Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc 2008;83:1087-94. [PMID: 18828967 DOI: 10.4065/83.10.1087] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
184 Baiocco S, Sah BR, Mallia A, Kelly-Morland C, Neji R, Stirling JJ, Jeljeli S, Bevilacqua A, Cook GJR, Goh V. Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. Eur J Nucl Med Mol Imaging 2019;46:1478-84. [PMID: 30919055 DOI: 10.1007/s00259-019-04306-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
185 Wang CY, Deng JY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. Oncotarget. 2015;6:18674-18682. [PMID: 26124180 DOI: 10.18632/oncotarget.4367] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
186 De B, Rhome R, Jairam V, Özbek U, Holcombe RF, Buckstein M, Ang C. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer 2018;21:889-99. [PMID: 29691758 DOI: 10.1007/s10120-018-0826-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
187 Yang MH, Ha IJ, Um JY, Ahn KS. Albendazole Exhibits Anti-Neoplastic Actions against Gastric Cancer Cells by Affecting STAT3 and STAT5 Activation by Pleiotropic Mechanism(s). Biomedicines 2021;9:362. [PMID: 33807326 DOI: 10.3390/biomedicines9040362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Ji X, Pan C, Li X, Gao Y, Xia L, Quan X, Lv J, Wang R. Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45. Oncol Lett 2017;13:841-6. [PMID: 28356967 DOI: 10.3892/ol.2016.5517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
189 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
190 Liu X, Lin K, Huang X, Xie W, Xiang D, Ding N, Hu C, Shen X, Xue X, Huang Y. Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis. J Cancer Res Clin Oncol 2020;146:555-68. [PMID: 32025866 DOI: 10.1007/s00432-019-03092-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Jun KH, Gholami S, Song TJ, Au J, Haddad D, Carson J, Chen CH, Mojica K, Zanzonico P, Chen NG, Zhang Q, Szalay A, Fong Y. A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. J Exp Clin Cancer Res 2014;33:2. [PMID: 24383569 DOI: 10.1186/1756-9966-33-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
192 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 46.0] [Reference Citation Analysis]
193 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434-011-1631-5] [Cited by in Crossref: 334] [Cited by in F6Publishing: 310] [Article Influence: 33.4] [Reference Citation Analysis]
194 Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, Yu J. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694-e701. [PMID: 22337686 DOI: 10.1259/bjr/29946900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
195 Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, Kim HI, An JY, Hyung WJ, Kim CB, Noh SH, Kim S, Cheong JH. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 2016;6:22172. [PMID: 26926953 DOI: 10.1038/srep22172] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
196 Dittmar Y, Rauchfuss F, Götz M, Scheuerlein H, Jandt K, Settmacher U. Impact of Clinical and Pathohistological Characteristics on the Incidence of Recurrence and Survival in Elderly Patients with Gastric Cancer. World J Surg 2012;36:338-45. [DOI: 10.1007/s00268-011-1395-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
197 Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut 2018;67:1780-92. [PMID: 28830912 DOI: 10.1136/gutjnl-2017-314408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
198 Davies AR, Forshaw MJ, Khan AA, Noorani AS, Patel VM, Strauss DC, Mason RC. Transhiatal esophagectomy in a high volume institution. World J Surg Oncol 2008;6:88. [PMID: 18715498 DOI: 10.1186/1477-7819-6-88] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
199 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
200 Mochiki E, Ogata K, Ohno T, Toyomasu Y, Haga N, Fukai Y, Aihara R, Ando H, Uchida N, Asao T, Kuwano H; North Kanto Gastric Cancer Study Group. Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2012;107:31-6. [PMID: 22617130 DOI: 10.1038/bjc.2012.222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
201 Liakakos T, Xeropotamos N, Ziogas D, Roukos D. EGFR as a Prognostic Marker for Gastric Cancer. World J Surg. 2008;32:1225-1226; author reply 1227-1229. [PMID: 18224475 DOI: 10.1007/s00268-007-9434-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
202 Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011;2:240-9. [PMID: 22811858 DOI: 10.3978/j.issn.2078-6891.2011.027] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
203 Li Z, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer 2018;21:977-87. [PMID: 29748876 DOI: 10.1007/s10120-018-0830-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
204 Soyfer V, Geva R, Michelson M, Inbar M, Shacham-Shmueli E, Corn BW. The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer. Radiat Oncol 2014;9:81. [PMID: 24655942 DOI: 10.1186/1748-717X-9-81] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
205 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
206 Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer 2018;118:331-7. [PMID: 29235564 DOI: 10.1038/bjc.2017.423] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
207 Hou Z, Ren W, Li S, Liu J, Sun Y, Yan J, Wan S. Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma. Oncotarget 2017;8:104444-54. [PMID: 29262652 DOI: 10.18632/oncotarget.22304] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
208 Nelen SD, Heuthorst L, Verhoeven RHA, Polat F, Kruyt PM, Reijnders K, Ferenschild FTJ, Bonenkamp JJ, Rutter JE, de Wilt JHW, Spillenaar Bilgen EJ. Impact of Centralizing Gastric Cancer Surgery on Treatment, Morbidity, and Mortality. J Gastrointest Surg. 2017;21:2000-2008. [PMID: 28815471 DOI: 10.1007/s11605-017-3531-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
209 Cai Z, Rui W, Li S, Fingerhut A, Sun J, Ma J, Zang L, Zhu Z, Zheng M. Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer. Front Oncol 2020;10:614785. [PMID: 33384963 DOI: 10.3389/fonc.2020.614785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
210 Allen S, Brown V, Prabhu P, Scott M, Rockall T, Preston S, Sultan J. A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol. BMJ Open 2018;8:e023190. [PMID: 30580268 DOI: 10.1136/bmjopen-2018-023190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
211 Mongan AM, Kalachand R, King S, O'Farrell NJ, Power D, Ravi N, Muldoon C, O'Byrne K, Reynolds JV. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Ir J Med Sci. 2015;184:417-423. [PMID: 24879337 DOI: 10.1007/s11845-014-1135-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
212 Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol 2014; 20(34): 12355-12358 [PMID: 25232273 DOI: 10.3748/wjg.v20.i34.12355] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
213 Katayama H, Tsuburaya A, Mizusawa J, Nakamura K, Katai H, Imamura H, Nashimoto A, Fukushima N, Sano T, Sasako M. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer 2019;22:1301-7. [PMID: 31264058 DOI: 10.1007/s10120-019-00981-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
214 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)60617-6] [Cited by in Crossref: 635] [Cited by in F6Publishing: 407] [Article Influence: 52.9] [Reference Citation Analysis]
215 von Wichert G, Seufferlein T. [Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?]. Internist (Berl) 2007;48:1335-42. [PMID: 17965842 DOI: 10.1007/s00108-007-1974-y] [Reference Citation Analysis]
216 Röcken C, Behrens HM, Böger C, Krüger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol 2016;69:70-5. [PMID: 26251521 DOI: 10.1136/jclinpath-2015-202980] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
217 Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the Treatment of Gastric Cancer. JMA J 2018;1:40-9. [PMID: 33748521 DOI: 10.31662/jmaj.2018-0006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
218 Guo C, Su J, Li Z, Xiao R, Wen J, Li Y, Zhang M, Zhang X, Yu D, Huang W, Chen WD, Wang YD. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget 2015;6:34402-13. [PMID: 26417930 DOI: 10.18632/oncotarget.5353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
219 Uslu A, Zengel B, İlhan E, Aykas A, Şimşek C, Üreyen O, Duran A, Okut G. Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage II-III gastric cancer: Longitudinal follow-up in a single center. Turk J Surg 2018;34:125-30. [PMID: 30023977 DOI: 10.5152/turkjsurg.2018.3846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
220 Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018;9:560-72. [PMID: 29998022 DOI: 10.21037/jgo.2018.03.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
221 Tran P, Nguyen C, Klempner SJ. Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int Neurourol J 2016;20:S131-140. [PMID: 27915478 DOI: 10.5213/inj.1632740.370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
222 Keld R, Guo B, Downey P, Cummins R, Gulmann C, Ang YS, Sharrocks AD. PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma. Br J Cancer. 2011;105:124-130. [PMID: 21673681 DOI: 10.1038/bjc.2011.187] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
223 Brenkman HJF, Gertsen EC, Vegt E, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Sandick JW, van Grieken NCT, Heisterkamp J, van Etten B, Haveman JW, Pierie JP, Jonker F, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wessels FJ, Haj Mohammad N, van Stel HF, Frederix GWJ, Siersema PD, Ruurda JP; PLASTIC Study Group. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study). BMC Cancer 2018;18:450. [PMID: 29678145 DOI: 10.1186/s12885-018-4367-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
224 Strauss J, Hershman DL, Buono D, McBride R, Clark-Garvey S, Woodhouse SA, Abrams JA, Neugut AI. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys 2010;76:1404-12. [PMID: 19540074 DOI: 10.1016/j.ijrobp.2009.03.050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
225 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
226 Chu H, Han N, Xu J. CMPK1 Regulated by miR-130b Attenuates Response to 5-FU Treatment in Gastric Cancer. Front Oncol 2021;11:637470. [PMID: 33816278 DOI: 10.3389/fonc.2021.637470] [Reference Citation Analysis]
227 Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol. 2014;21:569-574. [PMID: 24165900 DOI: 10.1245/s10434-013-3314-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
228 Shigeoka H, Imamoto H, Nishimura Y, Shimono T, Furukawa H, Imamura H, Yasuda T, Shiozaki H. Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma. World J Gastrointest Oncol 2010; 2(6): 282-286 [PMID: 21160641 DOI: 10.4251/wjgo.v2.i6.282] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
229 Lin JX, Wang ZK, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Huang CM, Li P. Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis. Cancer Commun (Lond) 2019;39:4. [PMID: 30744696 DOI: 10.1186/s40880-019-0350-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
230 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
231 Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther 2015;9:487-508. [PMID: 25609923 DOI: 10.2147/DDDT.S74127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
232 Shinde A, Novak J, Amini A, Chen YJ. The evolving role of radiation therapy for resectable and unresectable gastric cancer. Transl Gastroenterol Hepatol 2019;4:64. [PMID: 31559345 DOI: 10.21037/tgh.2019.08.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Wang Y, Lei X, Liu Z, Shan F, Ying X, Li Z, Ji J. Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. J Gastrointest Oncol 2021;12:237-48. [PMID: 34012622 DOI: 10.21037/jgo-20-374] [Reference Citation Analysis]
234 Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617-624. [PMID: 21203759 DOI: 10.1007/s00268-010-0935-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 8.2] [Reference Citation Analysis]
235 Li Z, Wang Y, Ying X, Shan F, Wu Z, Zhang L, Li S, Jia Y, Ren H, Ji J. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer 2019;19:80. [PMID: 30651085 DOI: 10.1186/s12885-019-5283-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
236 Farhan F, Ghalehtaki R, Mahdavi-Seresht S, Meysamie A, Yamrali M, Farazmand B, Mohammadi N, Saraee E, Mir MR, Mir A, Lashkari M, Salarvand S, Esmati E, Samiei F. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. J Gastrointest Cancer 2019;50:907-12. [PMID: 30402826 DOI: 10.1007/s12029-018-0155-7] [Reference Citation Analysis]
237 Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget 2017;8:30477-94. [PMID: 27802185 DOI: 10.18632/oncotarget.12955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
238 Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg. 2018;267:105-113. [PMID: 27759618 DOI: 10.1097/sla.0000000000002040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
239 Li Y, Wei Y, He Q, Wang X, Fan C, Li G. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep 2018;8:6223. [PMID: 29670115 DOI: 10.1038/s41598-018-24259-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
240 Yang K, Hu JK. Gastric cancer treatment: similarity and difference between China and Korea. Transl Gastroenterol Hepatol 2017;2:36. [PMID: 28529990 DOI: 10.21037/tgh.2017.04.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
241 Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacín A, Castells A, Piqué JM, Volant A, Metges JP. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg. 2008;12:1005-1014. [PMID: 17972143 DOI: 10.1007/s11605-007-0336-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
242 Schwab M, Brindl N, Studier-Fischer A, Tu T, Gsenger J, Pilgrim M, Friedrich M, Frey PE, Achilles C, Leuck A, Bürgel T, Feisst M, Klose C, Tenckhoff S, Dörr-Harim C, Mihaljevic AL. Postoperative complications and mobilisation following major abdominal surgery with vs. without fitness tracker-based feedback (EXPELLIARMUS): study protocol for a student-led multicentre randomised controlled trial (CHIR-Net SIGMA study group). Trials 2020;21:293. [PMID: 32293519 DOI: 10.1186/s13063-020-4220-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
243 Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother 2016;65:651-62. [PMID: 27020682 DOI: 10.1007/s00262-016-1826-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 11.8] [Reference Citation Analysis]
244 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
245 Koukourakis GV. Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World J Gastrointest Oncol 2011; 3(9): 131-136 [PMID: 22007277 DOI: 10.4251/wjgo.v3.i9.131] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
246 Thakur B, Devkota M, Chaudhary M. Management of Locally Advanced Esophageal Cancer. JNMA J Nepal Med Assoc 2021;59:409-16. [PMID: 34508544 DOI: 10.31729/jnma.4299] [Reference Citation Analysis]
247 Behrens A, Pech O, Graupe F, May A, Lorenz D, Ell C. Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. Dtsch Arztebl Int 2011;108:313-9. [PMID: 21629515 DOI: 10.3238/arztebl.2011.0313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
248 Hanna WC, Sudarshan M, Roberge D, David M, Waschke KA, Mayrand S, Alcindor T, Ferri LE. What is the optimal management of dysphagia in metastatic esophageal cancer? Curr Oncol 2012;19:e60-6. [PMID: 22514498 DOI: 10.3747/co.19.892] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
249 Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol 2018;13:69-78. [PMID: 29128908 DOI: 10.1007/s11523-017-0536-z] [Reference Citation Analysis]
250 Shi XJ, Wei Y, Ji B. Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment.Front Mol Biosci. 2020;7:203. [PMID: 33005629 DOI: 10.3389/fmolb.2020.00203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
251 Sinclair R, Navidi M, Griffin SM, Sumpter K. The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma. Ann R Coll Surg Engl 2016;98:396-400. [PMID: 27138851 DOI: 10.1308/rcsann.2016.0135] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
252 Mirkin KA, Hollenbeak CS, Wong J. Greater Lymph Node Retrieval Improves Survival in Node-Negative Resected Gastric Cancer in the United States. J Gastric Cancer 2017;17:306-18. [PMID: 29302371 DOI: 10.5230/jgc.2017.17.e35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
253 Liu Y, Zhang KC, Huang XH, Xi HQ, Gao YH, Liang WQ, Wang XX, Chen L. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes. World J Gastroenterol 2018; 24(2): 257-265 [PMID: 29375211 DOI: 10.3748/wjg.v24.i2.257] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
254 Zurleni T, Gjoni E, Ballabio A, Casieri R, Ceriani P, Marzoli L, Zurleni F. Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients. World Journal of Gastrointestinal Surgery 2013; 5(11): 287-293 [PMID: 24520426 DOI: 10.4240/wjgs.v5.i11.287] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
255 Weijs TJ, Ruurda JP, Nieuwenhuijzen GA, van Hillegersberg R, Luyer MD. Strategies to reduce pulmonary complications after esophagectomy. World J Gastroenterol 2013; 19(39): 6509-6514 [PMID: 24151374 DOI: 10.3748/wjg.v19.i39.6509] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
256 Fareed KR, Soomro IN, Hameed K, Arora A, Lobo DN, Parsons SL, Madhusudan S. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy. World J Gastroenterol 2012; 18(16): 1915-1920 [PMID: 22563171 DOI: 10.3748/wjg.v18.i16.1915] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
257 Wang T, Chen Y, Zhao L, Zhou H, Wu C, Zhang X, Zhou A, Jin J, Zhao D. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. J Cancer 2021;12:379-86. [PMID: 33391434 DOI: 10.7150/jca.46847] [Reference Citation Analysis]
258 Kosuga T, Ichikawa D, Otsuji E. Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol 2016;1:75. [PMID: 28138641 DOI: 10.21037/tgh.2016.09.08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
259 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer 2016;7:88-94. [PMID: 26722364 DOI: 10.7150/jca.13248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
261 Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol 2007;14:3290-2. [PMID: 17932722 DOI: 10.1245/s10434-007-9575-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
262 Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Lai ST, Jiang GL, Zhao KL. Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol 2014;19:297-302. [PMID: 23690261 DOI: 10.1007/s10147-013-0564-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
263 Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, Yoshikawa T, Kobayashi D, Tanaka C, Fujiwara M. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206-212. [PMID: 24022130 DOI: 10.1007/s10120-013-0299-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
264 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
265 McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep. 2012;14:342-349. [PMID: 22544559 DOI: 10.1007/s11912-012-0239-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
266 Li H, Jin X, Liu P, Hong W. Time to local recurrence as a predictor of survival in unrecetable gastric cancer patients after radical gastrectomy. Oncotarget 2017;8:89203-13. [PMID: 29179512 DOI: 10.18632/oncotarget.19038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
267 Chen H, Wu S, Kundra A, Aja Onu I, Gotlieb V, Wang JC. Gastric Perforation in a Patient Receiving Neoadjuvant Chemoradiotherapy. World J Oncol 2015;6:383-6. [PMID: 28983335 DOI: 10.14740/wjon924w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
268 Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87-104. [PMID: 25061536 DOI: 10.5230/jgc.2014.14.2.87] [Cited by in Crossref: 119] [Cited by in F6Publishing: 118] [Article Influence: 17.0] [Reference Citation Analysis]
269 Zhong J, Zhao W, Ma W, Ren F, Qi S, Zheng J, Wang X, Lv T, Su Z, Yin H, Ren J, Huan Y. DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases. Medicine (Baltimore) 2016;95:e3236. [PMID: 27043694 DOI: 10.1097/MD.0000000000003236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
270 Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A. Personalised Treatment in Gastric Cancer: Myth or Reality? Curr Oncol Rep. 2016;18:41. [PMID: 27215435 DOI: 10.1007/s11912-016-0525-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
271 Lee Y, Min SH, Park KB, Park YS, Kim JW, Ahn SH, Kim JW, Park DJ, Lee KW, Kim HH. Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis. J Gastric Cancer. 2018;18:58-68. [PMID: 29629221 DOI: 10.5230/jgc.2018.18.e5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
272 Kohlruss M, Ott K, Grosser B, Jesinghaus M, Slotta-Huspenina J, Novotny A, Hapfelmeier A, Schmidt T, Gaida MM, Weichert W, Keller G. Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers (Basel) 2021;13:1048. [PMID: 33801374 DOI: 10.3390/cancers13051048] [Reference Citation Analysis]
273 Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget. 2017;8:111795-111806. [PMID: 29340092 DOI: 10.18632/oncotarget.22909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
274 Liu F, Yang L, Wu Y, Li C, Zhao J, Keranmu A, Zheng H, Huang D, Wang L, Tong T, Xu J, Zhu J, Cai S, Xu Y. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res 2016;28:589-97. [PMID: 28174487 DOI: 10.21147/j.issn.1000-9604.2016.06.05] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
275 Chen M, Lu J, Wei W, Lv Y, Zhang X, Yao Y, Wang L, Ling T, Zou X. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. Onco Targets Ther 2018;11:6705-22. [PMID: 30349304 DOI: 10.2147/OTT.S161198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
276 Gallego J, Cervantes A, Pericay C, Isla D. SEOM clinical guidelines for the treatment of oesophageal cancer. Clin Transl Oncol 2011;13:520-4. [PMID: 21821484 DOI: 10.1007/s12094-011-0691-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Zhang Y, Luo Z, Yang L, Chen S, Chen C, Lin Z. The association between four SNPs of X-ray repair cross complementing protein 1 and the sensitivity to radiotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett 2016;11:3508-14. [PMID: 27123143 DOI: 10.3892/ol.2016.4384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
278 Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol 2015; 21(9): 2711-2718 [PMID: 25759540 DOI: 10.3748/wjg.v21.i9.2711] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
279 Hu Y, McMurry TL, Goudreau B, Leick KM, Le TM, Zaydfudim VM. Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma. J Gastrointest Surg 2020;24:2212-8. [PMID: 31515762 DOI: 10.1007/s11605-019-04393-9] [Reference Citation Analysis]
280 Jin H, Sun J, Zhu K, Liu X, Zhang Q, Shen Q, Gao Y, Yu J. The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up. Onco Targets Ther. 2017;10:2655-2664. [PMID: 28579803 DOI: 10.2147/ott.s135641] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
281 Sanjeevaiah A, Park H, Fangman B, Porembka M. Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. Cancers (Basel) 2020;12:E592. [PMID: 32150838 DOI: 10.3390/cancers12030592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Aytaç E, Aslan F, Çicek B, Erdamar S, Gürses B, Güven K, Falay O, Karahasanoğlu T, Selçukbiricik F, Selek U, Atalar B, Balık E, Tözün N, Rozanes İ, Arıcan A, Hamzaoğlu İ, Baca B, Molinas Mandel N, Saruç M, Göksel S, Demir G, Ağaoğlu F, Yakıcıer C, Özbek U, Özben V, Özyar E, Güner AL, Er Ö, Kaban K, Bölükbaşı Y, Buğra D, Group Tİ. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group. Turk J Gastroenterol 2019;30:584-98. [PMID: 30541724 DOI: 10.5152/tjg.2018.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Sakin A, Atci MM, Aldemir MN, Akagündüz B, Şahin S, Arıcı S, Secmeler S, Cihan S. The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy. Cureus 2021;13:e14639. [PMID: 34046274 DOI: 10.7759/cureus.14639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Zhang XQ, Zhang HM, Sun XE, Yuan ZJ, Feng YG. Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med 2015;9:105-11. [PMID: 25452783 DOI: 10.3892/etm.2014.2077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
285 Rim CH, Shin IS, Lee HY, Yoon WS, Park S. Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review. Cancers (Basel) 2020;12:E2125. [PMID: 32751879 DOI: 10.3390/cancers12082125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
286 Borg D, Hedner C, Nodin B, Larsson A, Johnsson A, Eberhard J, Jirström K. Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin Pathol 2016;16:13. [PMID: 27478410 DOI: 10.1186/s12907-016-0034-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
287 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol 2018; 10(9): 271-281 [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
289 Feng W, Wang Y, Chen S, Zhu X. Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer. Aging (Albany NY) 2020;12:24333-44. [PMID: 33259333 DOI: 10.18632/aging.202238] [Reference Citation Analysis]
290 Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33. [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136] [Cited by in Crossref: 466] [Cited by in F6Publishing: 253] [Article Influence: 51.8] [Reference Citation Analysis]
291 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
292 Brenkman HJF, Visser E, van Rossum PSN, Siesling S, van Hillegersberg R, Ruurda JP. Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands. Ann Surg Oncol 2017;24:1761-9. [PMID: 28353020 DOI: 10.1245/s10434-017-5820-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
293 Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: A review. World J Gastrointest Oncol 2018; 10(11): 398-409 [PMID: 30487951 DOI: 10.4251/wjgo.v10.i11.398] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
294 Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, Park YS, Oh ST, Yook JH, Kim BS, Kang YK. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-33. [PMID: 25614467 DOI: 10.1007/s10120-015-0464-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
295 Fontana E, Smyth EC. Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol. 2016;8:113-125. [PMID: 26929787 DOI: 10.1177/1758834015616935] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
296 Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Transl Gastroenterol Hepatol 2020;5:17. [PMID: 32258521 DOI: 10.21037/tgh.2019.09.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
297 Rausei S, Ruspi L, Galli F, Pappalardo V, Di Rocco G, Martignoni F, Frattini F, Rovera F, Boni L, Dionigi G. Seventh tumor-node-metastasis staging of gastric cancer: Five-year follow-up. World J Gastroenterol 2016; 22(34): 7748-7753 [PMID: 27678357 DOI: 10.3748/wjg.v22.i34.7748] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
298 Li Z, Wu C, Wu J, Ji M, Shi L, Jiang J, Xu B, Yuan J. Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells. Oncol Lett 2014;8:1603-7. [PMID: 25202376 DOI: 10.3892/ol.2014.2368] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
299 Jung YS, Lim J, Jung KW, Ryu J, Won YJ. Metachronous Second Primary Malignancies after Head and Neck Cancer in a Korean Cohort (1993-2010). PLoS One 2015;10:e0134160. [PMID: 26218068 DOI: 10.1371/journal.pone.0134160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
300 Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB, Li WF. Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One 2014;9:e107061. [PMID: 25211331 DOI: 10.1371/journal.pone.0107061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
301 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
302 Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol. 2010;3:31. [PMID: 20828403 DOI: 10.1186/1756-8722-3-31] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
303 Song T, Yao Q, Qu J, Zhang H, Zhao Y, Qin J, Feng W, Zhang S, Han X, Wang S, Yan X, Li H. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol 2021;31:1391-400. [PMID: 32901300 DOI: 10.1007/s00330-020-07248-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
304 Hisashige A, Sasako M, Nakajima T. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer. 2013;13:443. [PMID: 24079752 DOI: 10.1186/1471-2407-13-443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
305 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
306 Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist 2014;19:367-74. [PMID: 24664485 DOI: 10.1634/theoncologist.2013-0178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
307 Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105:1600-1607. [PMID: 24108812 DOI: 10.1093/jnci/djt270] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
308 Turgeon MK, Maithel SK, Shah MM. ASO Author Reflections: A Surgery-First Approach for Patients With Clinical Stage 1 Signet Ring Cell Gastric Adenocarcinoma. Ann Surg Oncol 2020;27:781-2. [PMID: 32533396 DOI: 10.1245/s10434-020-08718-w] [Reference Citation Analysis]
309 Ibrahim M, Gilbert K. Management of gastric cancer in Indian population. Transl Gastroenterol Hepatol 2017;2:64. [PMID: 28905005 DOI: 10.21037/tgh.2017.07.02] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
310 Tianhang L, Guoen F, Jianwei B, Liye M. The effect of perineural invasion on overall survival in patients with gastric carcinoma. J Gastrointest Surg. 2008;12:1263-1267. [PMID: 18463928 DOI: 10.1007/s11605-008-0529-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
311 Ramachandra, Goel V, Raju K, Rao TS, Patnaik, Nusrath, Santa, Murthy S. Prospective Randomized Controlled Study Comparing Primary Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Gastric Carcinoma. Indian J Surg Oncol 2019;10:245-50. [PMID: 31168243 DOI: 10.1007/s13193-019-00908-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Liu F, Tong T, Huang D, Yuan W, Li D, Lin J, Cai S, Xu Y, Chen W, Sun Y, Zhuang J. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial. BMJ Open 2019;9:e017637. [PMID: 30700474 DOI: 10.1136/bmjopen-2017-017637] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
313 Rao S, Cunningham D. Survival from cancer of the stomach in England and Wales up to 2001. Br J Cancer 2008;99 Suppl 1:S19-20. [PMID: 18813247 DOI: 10.1038/sj.bjc.6604575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
314 Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 2014;14:148. [PMID: 24589307 DOI: 10.1186/1471-2407-14-148] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
315 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
316 Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;. [PMID: 30949777 DOI: 10.1007/s10120-019-00956-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
317 Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut 2019;68:1918-27. [PMID: 30852560 DOI: 10.1136/gutjnl-2018-317624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
318 Powell AGMT, Eley C, Chin C, Coxon AH, Christian A, Lewis WG; South East Wales Oesophagogastric Cancer Collaborative. Prognostic significance of serum inflammatory markers in esophageal cancer. Esophagus 2021;18:267-77. [PMID: 32865623 DOI: 10.1007/s10388-020-00772-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
319 Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z, Zheng G, Pan H, Wang H, Yang X, Zhang Y. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12:2072-2084. [PMID: 30242969 DOI: 10.1002/1878-0261.12385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
320 Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34-42. [PMID: 23430266 DOI: 10.1007/s10120-013-0239-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
321 Fujimoto D, Goi T, Koneri K, Hirono Y. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer. Oncotarget 2018;9:15208-18. [PMID: 29632637 DOI: 10.18632/oncotarget.24622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
322 Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50-55. [PMID: 21340667 DOI: 10.1007/s10120-011-0007-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 7.6] [Reference Citation Analysis]
323 Sun LB, Zhao GJ, Ding DY, Song B, Hou RZ, Li YC. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. World J Surg Oncol. 2014;12:280. [PMID: 25200958 DOI: 10.1186/1477-7819-12-280] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
324 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014; 6(10): 403-406 [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
325 Kumar NAN, Jose A, Usman N, Rajan K, Munisamy M, Shetty PS, Rao M. Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges. Langenbecks Arch Surg 2021. [PMID: 34505199 DOI: 10.1007/s00423-021-02314-6] [Reference Citation Analysis]
326 Saviaro H, Rintala J, Kauppila JH, Yannopoulos F, Meriläinen S, Koivukangas V, Huhta H, Helminen O, Saarnio J. Thirty years of esophageal cancer surgery in Oulu University Hospital. J Thorac Dis 2021;13:4638-49. [PMID: 34527305 DOI: 10.21037/jtd-21-520] [Reference Citation Analysis]
327 Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. Radiat Oncol 2014;9:9. [PMID: 24398302 DOI: 10.1186/1748-717X-9-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
328 Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1-9. [PMID: 18373171 DOI: 10.1007/s10120-007-0448-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
329 Tye H, Jenkins BJ. Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. Cancer Sci. 2013;104:1139-1145. [PMID: 23710764 DOI: 10.1111/cas.12205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
330 Orsenigo E, Bissolati M, Socci C, Chiari D, Muffatti F, Nifosi J, Staudacher C. Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer. 2014;17:733-744. [PMID: 24399492 DOI: 10.1007/s10120-013-0327-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
331 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
332 Curtis NJ, Noble F, Bailey IS, Kelly JJ, Byrne JP, Underwood TJ. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol. 2014;109:202-207. [PMID: 24243140 DOI: 10.1002/jso.23484] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
333 Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019;23:885-894. [PMID: 30374818 DOI: 10.1007/s11605-018-4007-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
334 Graham Martínez C, Knijn N, Verheij M, Nagtegaal ID, van der Post RS. Tumour deposits are a significant prognostic factor in gastric cancer - a systematic review and meta-analysis. Histopathology 2019;74:809-16. [PMID: 30376189 DOI: 10.1111/his.13781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
335 Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol 2014; 6(8): 263-274 [PMID: 25132924 DOI: 10.4251/wjgo.v6.i8.263] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
336 Xiong HL, Zhou SW, Sun AH, He Y, Li J, Yuan X. MicroRNA197 reverses the drug resistance of fluorouracilinduced SGC7901 cells by targeting mitogenactivated protein kinase 1. Mol Med Rep. 2015;12:5019-5025. [PMID: 26151540 DOI: 10.3892/mmr.2015.4052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
337 Beeharry MK, Ni ZT, Yang ZY, Zheng YN, Feng RH, Liu WT, Yan C, Yao XX, Li C, Yan M, Zhu ZG. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial. BMC Cancer 2020;20:224. [PMID: 32183736 DOI: 10.1186/s12885-020-6701-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
338 van der Werf LR, Eshuis WJ, Draaisma WA, van Etten B, Gisbertz SS, van der Harst E, Liem MSL, Lemmens VEPP, Wijnhoven BPL, Besselink MG, van Berge Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer. J Gastrointest Surg 2019;23:2327-37. [PMID: 30820797 DOI: 10.1007/s11605-019-04133-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
339 Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 2014;110:275-84. [PMID: 25042700 DOI: 10.1002/jso.23633] [Cited by in Crossref: 78] [Cited by in F6Publishing: 87] [Article Influence: 11.1] [Reference Citation Analysis]
340 Wei KK, Jiang L, Wei YY, Wang YF, Qian XK, Dai Q, Guan QL. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. Tumour Biol 2014;35:8721-31. [PMID: 24870596 DOI: 10.1007/s13277-014-2128-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
341 Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis 2017;9:S697-704. [PMID: 28815065 DOI: 10.21037/jtd.2017.03.159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
342 Díaz Del Arco C, Ortega Medina L, Estrada Muñoz L, García Gómez de Las Heras S, Fernández Aceñero MJ. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histol Histopathol 2021;36:587-613. [PMID: 33565601 DOI: 10.14670/HH-18-309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Liu J, Su M, Wang J, Zhang G, Zhou J, Zhang A, Ren Z, Zheng X, Hong S, Wang S, Zhang R. A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget 2017;8:14058-67. [PMID: 27740935 DOI: 10.18632/oncotarget.12573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
344 Chen C, Tang X, Liu Y, Zhu J, Liu J. Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review). Int J Oncol 2019;54:1511-24. [PMID: 30896792 DOI: 10.3892/ijo.2019.4751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
345 Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020;6:1231-40. [PMID: 32469386 DOI: 10.1001/jamaoncol.2020.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
346 Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, Oh DY, Bang YJ, Im SA. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Res Treat 2020;52:1178-87. [PMID: 32599979 DOI: 10.4143/crt.2020.313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
347 Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I. Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 2018;3:e000386. [PMID: 30094072 DOI: 10.1136/esmoopen-2018-000386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
348 Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R. Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent. Ann Surg Oncol. 2015;22 Suppl 3:S1292-S1300. [PMID: 26334295 DOI: 10.1245/s10434-015-4840-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
349 Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, Shi M, Xu W, Zhu Z, Liu W, Yan C, Li C, Liu B, Yan M. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11:6093. [PMID: 33257672 DOI: 10.1038/s41467-020-19965-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
350 Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol 2015;6:516-23. [PMID: 26487946 DOI: 10.3978/j.issn.2078-6891.2015.040] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
351 Xiao H, Quan H, Pan S, Yin B, Luo W, Huang G, Ouyang Y. Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion. J Cancer Res Clin Oncol 2018;144:1143-54. [PMID: 29572591 DOI: 10.1007/s00432-018-2630-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
352 Kosovec JE, Zaidi AH, Pounardjian TS, Jobe BA. The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Front Oncol 2018;8:610. [PMID: 30619750 DOI: 10.3389/fonc.2018.00610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
353 Yuan SQ, Wu WJ, Qiu MZ, Wang ZX, Yang LP, Jin Y, Yun JP, Gao YH, Li YH, Zhou ZW, Wang F, Xu RH. Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. J Cancer 2017;8:3498-505. [PMID: 29151934 DOI: 10.7150/jca.19879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
354 Costa WL, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, Begnami M, Silva MJ, Fanelli MF, Mello CA. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195. [PMID: 22992263 DOI: 10.1186/1477-7819-10-195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
355 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152-1160. [PMID: 23017669 DOI: 10.1016/s1470-2045(12)70348-0] [Cited by in Crossref: 224] [Cited by in F6Publishing: 103] [Article Influence: 24.9] [Reference Citation Analysis]
356 Tan P. Divide and conquer: progress in the molecular stratification of cancer. Yonsei Med J 2009;50:464-73. [PMID: 19718393 DOI: 10.3349/ymj.2009.50.4.464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
357 Li Z, Shan F, Ying X, Zhang Y, E JY, Wang Y, Ren H, Su X, Ji J. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. JAMA Surg 2019;154:1093-101. [PMID: 31553463 DOI: 10.1001/jamasurg.2019.3473] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 26.0] [Reference Citation Analysis]
358 Sun KY, Hu HT, Chen SL, Ye JN, Li GH, Chen LD, Peng JJ, Feng ST, Yuan YJ, Hou X, Wu H, Li X, Wu TF, Wang W, Xu JB. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. BMC Cancer 2020;20:468. [PMID: 32450841 DOI: 10.1186/s12885-020-06970-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
359 Gockel I, Hoffmeister A, Lordick F. [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg 2015;86:1014-22. [PMID: 26374651 DOI: 10.1007/s00104-015-0077-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
360 Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 2016;34:2721-2727. [PMID: 27298411 DOI: 10.1200/jco.2015.65.7692] [Cited by in Crossref: 115] [Cited by in F6Publishing: 65] [Article Influence: 23.0] [Reference Citation Analysis]
361 Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017;47:899-907. [PMID: 28247105 DOI: 10.1007/s00595-017-1473-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
362 Vitz S, Göbel H, Leibl B, Aigner T, Grabenbauer GG. Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery : Long-term results. Strahlenther Onkol 2018;194:1007-16. [PMID: 29872880 DOI: 10.1007/s00066-018-1320-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
363 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
364 Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol 2015;39:487-95. [PMID: 25634752 DOI: 10.1097/PAS.0000000000000356] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
365 Zaidi A, Khan A, Duval C, Haider K, Ahmed O, Dueck DA, Brunet B, Gardiner D, Ahmed S. Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience. Curr Oncol 2021;28:1262-73. [PMID: 33802661 DOI: 10.3390/curroncol28020120] [Reference Citation Analysis]
366 Powell AGMT, Parkinson D, Patel N, Chan D, Christian A, Lewis WG. Prognostic Significance of Serum Inflammatory Markers in Gastric Cancer. J Gastrointest Surg 2018;22:595-605. [PMID: 29234999 DOI: 10.1007/s11605-017-3597-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
367 Wang C, Hu Z, Zhu Z, Zhang X, Wei Z, Zhang Y, Hu D, Cai Q. The MSHA strain of Pseudomonas aeruginosa (PA-MSHA) inhibits gastric carcinoma progression by inducing M1 macrophage polarization. Tumour Biol 2016;37:6913-21. [PMID: 26662800 DOI: 10.1007/s13277-015-4451-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
368 Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, Sakuramoto S, Kikuchi S, Watanabe M. Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today. 2015;45:68-77. [PMID: 25352012 DOI: 10.1007/s00595-014-1060-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
369 Batista TP, de Mendonça LM, Fassizoli-Fonte AL. The role of perioperative radiotherapy in gastric cancer. Oncol Rev 2012;6:e23. [PMID: 25992221 DOI: 10.4081/oncol.2012.e23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
370 de Jesus VHF, da Costa WL Jr, Felismino TC, Calsavara VF, Diniz AL, de Castro Ribeiro HS, de Godoy AL, de Farias IC, Coimbra FJF. Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. J Gastrointest Oncol 2019;10:1110-9. [PMID: 31949928 DOI: 10.21037/jgo.2019.10.04] [Reference Citation Analysis]
371 Kauppi J, Räsänen J, Sihvo E, Huuhtanen R, Nelskylä K, Salo J. Open versus minimally invasive esophagectomy: clinical outcomes for locally advanced esophageal adenocarcinoma. Surg Endosc 2015;29:2614-9. [PMID: 25480610 DOI: 10.1007/s00464-014-3978-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
372 Xu HY, Xu WL, Wang LQ, Chen MB, Shen HL. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis. PLoS One. 2014;9:e95371. [PMID: 24740294 DOI: 10.1371/journal.pone.0095371] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
373 Calvo FA, Sole CV, Marsiglia H, Alvarado E, Ferrer C, Czito B. Intraoperative radiotherapy for gastrointestinal malignancies: contemporary outcomes with multimodality therapy. Curr Oncol Rep 2015;17:419. [PMID: 25416313 DOI: 10.1007/s11912-014-0419-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
374 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
375 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
376 Wilke H, Stahl M. [Therapy in gastric cancer. From an oncological perspective]. Chirurg. 2009;80:1023-1027. [PMID: 19902288 DOI: 10.1007/s00104-009-1735-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
377 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
378 顾军, 王玉生, 王梅, 李咏梅, 王雅杰. 希罗达加奥沙利铂治疗晚期贲门癌46例. 世界华人消化杂志 2008; 16(30): 3443-3447 [DOI: 10.11569/wcjd.v16.i30.3443] [Reference Citation Analysis]
379 Piessen G, Messager M, Le Malicot K, Robb WB, Di Fiore F, Guilbert M, Moreau M, Christophe V, Adenis A, Mariette C. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002. BMC Cancer. 2013;13:281. [PMID: 23758655 DOI: 10.1186/1471-2407-13-281] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
380 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
381 Gao L, Li J, He J, Liang L, He Z, Yue C, Jin X, Luo G, Zhou Y. CD90 affects the biological behavior and energy metabolism level of gastric cancer cells by targeting the PI3K/AKT/HIF-1α signaling pathway. Oncol Lett 2021;21:191. [PMID: 33574930 DOI: 10.3892/ol.2021.12451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Sci Rep 2019;9:12511. [PMID: 31467357 DOI: 10.1038/s41598-019-48929-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
383 Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15:146-151. [PMID: 23355076 DOI: 10.1007/s11912-013-0298-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
384 Lin JX, Wang ZK, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Huang CM, Li P. Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer. J Gastrointest Surg 2021;25:387-96. [PMID: 32016671 DOI: 10.1007/s11605-020-04523-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
385 Weng X, Zhang H, Ye J, Kan M, Liu F, Wang T, Deng J, Tan Y, He L, Liu Y. Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer. Sci Rep 2015;5:10154. [PMID: 25959250 DOI: 10.1038/srep10154] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
386 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
387 Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials 2021;22:753. [PMID: 34717717 DOI: 10.1186/s13063-021-05617-7] [Reference Citation Analysis]
388 Park S, Woo Y, Kim H, Lee YC, Choi S, Hyung WJ, Noh SH. In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer. J Gastric Cancer 2010;10:155-61. [PMID: 22076180 DOI: 10.5230/jgc.2010.10.4.155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
389 Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J Gastroenterol 2016; 22(29): 6619-6628 [PMID: 27547005 DOI: 10.3748/wjg.v22.i29.6619] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
390 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 218] [Article Influence: 113.0] [Reference Citation Analysis]
391 Al-Kaabi A, van der Post RS, Huising J, Rosman C, Nagtegaal ID, Siersema PD. Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis. United European Gastroenterol J 2020;8:35-43. [PMID: 32213055 DOI: 10.1177/2050640619879007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
392 Topal B, Demey K, Topal H, Jaekers J, Van Cutsem E, Vandecaveye V, Sagaert X, Prenen H. Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial. BMC Cancer 2017;17:771. [PMID: 29149865 DOI: 10.1186/s12885-017-3730-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
394 Sun H, Zhou R, Zheng Y, Wen Z, Zhang D, Zeng D, Wu J, Huang Z, Rong X, Huang N, Sun L, Bin J, Liao Y, Shi M, Liao W. CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy. Oncogene 2021. [PMID: 34262130 DOI: 10.1038/s41388-021-01932-0] [Reference Citation Analysis]
395 Wang Y, Liu Z, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Front Oncol 2020;10:613988. [PMID: 33392098 DOI: 10.3389/fonc.2020.613988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
396 Wang X, Lin Y, Lan F, Yu Y, Ouyang X, Liu W, Xie F, Wang X, Huang Q. BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Med Oncol 2014;31:249. [PMID: 25267570 DOI: 10.1007/s12032-014-0249-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
397 Baranov NS, van Workum F, van der Maas J, Kouwenhoven E, van Det M, van den Wildenberg FJH, Polat F, Nieuwenhuijzen GAP, Luyer MDP, Rosman C. The Influence of Age on Complications and Overall Survival After Ivor Lewis Totally Minimally Invasive Esophagectomy. J Gastrointest Surg. 2019;23:1293-1300. [PMID: 30565069 DOI: 10.1007/s11605-018-4062-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
398 Wang MJ, Li C, Sun Y, Shen FJ, Wang CB. Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials. Oncotarget 2017;8:102880-7. [PMID: 29262530 DOI: 10.18632/oncotarget.21983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Mann C, Hadzijusufovic E, Lang H, Grimminger PP. Fully robotic Ivor-Lewis esophagectomy (RAMIE4) for esophageal cancer after emergency surgery and ligation of the gastroduodenal artery. J Int Med Res 2019;47:1025-9. [PMID: 30543139 DOI: 10.1177/0300060518814682] [Reference Citation Analysis]
400 Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li XX, Jiang LH, Wang Y, Zhu SM, Mao WM. Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Med Oncol 2015;32:396. [PMID: 25432700 DOI: 10.1007/s12032-014-0396-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
401 Xu W, Beeharry MK, Liu W, Yan M, Zhu Z. Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. Biomed Res Int 2016;2016:3923585. [PMID: 28105420 DOI: 10.1155/2016/3923585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
402 Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery 2017;162:285-94. [PMID: 28578142 DOI: 10.1016/j.surg.2017.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
403 Park DJ, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, Yoon SS. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1508-15. [PMID: 26259755 DOI: 10.1245/s10434-015-4790-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
404 Sura K, Ye H, Vu CC, Robertson JM, Kabolizadeh P. How many lymph nodes are enough?-defining the extent of lymph node dissection in stage I-III gastric cancer using the National Cancer Database. J Gastrointest Oncol 2018;9:1168-75. [PMID: 30603138 DOI: 10.21037/jgo.2018.09.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
405 Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 2009;135:29-38. [PMID: 18523800 DOI: 10.1007/s00432-008-0425-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
406 Benevento I, Bulzonetti N, De Felice F, Musio D, Vergine M, Tombolini V. The role of different adjuvant therapies in locally advanced gastric adenocarcinoma. Oncotarget 2018;9:34022-9. [PMID: 30338043 DOI: 10.18632/oncotarget.26106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
407 Warschkow R, Baechtold M, Leung K, Schmied BM, Nussbaum DP, Gloor B, Blazer Iii DG, Worni M. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer. 2018;21:324-337. [PMID: 28646258 DOI: 10.1007/s10120-017-0742-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
408 Zhang S, Liu Y, Jiao Z, Li Z, Wang J, Li C, Qu X, Xu L. Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study. Front Oncol 2021;11:603031. [PMID: 33763350 DOI: 10.3389/fonc.2021.603031] [Reference Citation Analysis]
409 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG)., Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [PMID: 31023318 DOI: 10.1186/s12885-019-5545-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
410 Yabusaki N, Yamada S, Murai T, Kanda M, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Koike M. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol. 2015;3:435-441. [PMID: 25798282 DOI: 10.3892/mco.2014.462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
411 Long D, Yu PC, Huang W, Luo YL, Zhang S. Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer. Medicine (Baltimore) 2016;95:e5235. [PMID: 27858875 DOI: 10.1097/MD.0000000000005235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
412 Buckley AM, Lynam-Lennon N, Kennedy SA, Dunne MR, Aird JJ, Foley EK, Clarke N, Ravi N, O'Toole D, Reynolds JV, Kennedy BN, O'Sullivan J. Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma. Oncotarget 2018;9:33634-47. [PMID: 30263091 DOI: 10.18632/oncotarget.25950] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
413 Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH, Meyer HJ. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol 2017;2:53. [PMID: 28616608 DOI: 10.21037/tgh.2017.05.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
414 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
415 Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53. [PMID: 26989391 DOI: 10.1159/000440638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
416 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Ann Gastroenterol Surg 2020;4:352-9. [PMID: 32724878 DOI: 10.1002/ags3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Simonsen C, Thorsen-Streit S, Sundberg A, Djurhuus SS, Mortensen CE, Qvortrup C, Pedersen BK, Svendsen LB, de Heer P, Christensen JF. Effects of high-intensity exercise training on physical fitness, quality of life and treatment outcomes after oesophagectomy for cancer of the gastro-oesophageal junction: PRESET pilot study. BJS Open 2020;4:855-64. [PMID: 32856785 DOI: 10.1002/bjs5.50337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
419 Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M. Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. Onco Targets Ther 2015;8:1149-56. [PMID: 26045669 DOI: 10.2147/OTT.S82624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
420 Yu Y, Fang Y, Shen Z, Wang Y, Yan M, Cao H, Liu Y, Wang X, Cui Y, Liu F, Chen W, Li W, Li Q, Jiang H, Sun Y, Liu T. Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist. 2019;. [PMID: 31239311 DOI: 10.1634/theoncologist.2019-0416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
421 Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. [PMID: 25526802 DOI: 10.1186/1471-2407-14-984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
422 Mukherjee S, Hurt C, Radhakrishna G, Gwynne S, Bateman A, Gollins S, Hawkins MA, Canham J, Grabsch HI, Falk S, Sharma RA, Ray R, Roy R, Cox C, Maynard N, Nixon L, Sebag-Montefiore DJ, Maughan T, Griffiths GO, Crosby TDL. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. Eur J Cancer 2021;153:153-61. [PMID: 34157617 DOI: 10.1016/j.ejca.2021.05.020] [Reference Citation Analysis]
423 Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-96. [PMID: 25851942 DOI: 10.1007/s10120-015-0490-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
424 Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71. [PMID: 21327926 DOI: 10.1007/s10120-011-0011-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
425 Li Z, Gao X, Peng X, May Chen MJ, Li Z, Wei B, Wen X, Wei B, Dong Y, Bu Z, Wu A, Wu Q, Tang L, Li Z, Liu Y, Zhang L, Jia S, Zhang L, Shan F, Zhang J, Wu X, Ji X, Ji K, Wu X, Shi J, Xing X, Wu J, Lv G, Shen L, Ji X, Liang H, Ji J. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv 2020;6:eaay4211. [PMID: 32133402 DOI: 10.1126/sciadv.aay4211] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
426 Sun Z, Zhu RJ, Yang GF, Li Y. Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ScientificWorldJournal 2014;2014:418694. [PMID: 25136668 DOI: 10.1155/2014/418694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
427 Baiocchi GL, Giacopuzzi S, Marrelli D, Reim D, Piessen G, Matos da Costa P, Reynolds JV, Meyer HJ, Morgagni P, Gockel I, Lara Santos L, Jensen LS, Murphy T, Preston SR, Ter-Ovanesov M, Fumagalli Romario U, Degiuli M, Kielan W, Mönig S, Kołodziejczyk P, Polkowski W, Hardwick R, Pera M, Johansson J, Schneider PM, de Steur WO, Gisbertz SS, Hartgrink H, van Sandick JW, Portolani N, Hölscher AH, Botticini M, Roviello F, Mariette C, Allum W, De Manzoni G. International consensus on a complications list after gastrectomy for cancer. Gastric Cancer 2019;22:172-89. [PMID: 29846827 DOI: 10.1007/s10120-018-0839-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
428 Keskin M, Bayraktar A, Sivirikoz E, Yegen G, Karip B, Saglam E, Bulut MT, Balik E. Sparing Sphincters and Laparoscopic Resection Improve Survival by Optimizing the Circumferential Resection Margin in Rectal Cancer Patients. Medicine (Baltimore) 2016;95:e2669. [PMID: 26844498 DOI: 10.1097/MD.0000000000002669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
429 Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48-63. [PMID: 24216698 DOI: 10.3390/cancers5010048] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 12.8] [Reference Citation Analysis]
430 Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open 2017;2:e000130. [PMID: 28761726 DOI: 10.1136/esmoopen-2016-000130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
431 李向柯, 樊青霞. 食管癌药物治疗的研究进展. 世界华人消化杂志 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
432 Li ZH, Xie PY, Zhang DF, Li YJ, Wu L, Dong J, Xiao J, Liu ZY. Nomogram for predicting disease-free survival among a multicenter cohort of Chinese patients with locally advanced rectal cancer. Cancer Manag Res 2019;11:2471-83. [PMID: 31114319 DOI: 10.2147/CMAR.S196614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
433 Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg 2010;34:2821-9. [PMID: 20827475 DOI: 10.1007/s00268-010-0783-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
434 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 15.6] [Reference Citation Analysis]
435 Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer 2014;45:325-33. [PMID: 24756830 DOI: 10.1007/s12029-014-9601-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
436 Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterol Res Pract 2017;2017:5651903. [PMID: 28785280 DOI: 10.1155/2017/5651903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
437 Jayaprakash N, O'Kelly F, Lim KT, Reynolds JV. Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: Case report of a surgically challenging condition. Patient Saf Surg. 2009;3:23. [PMID: 19785744 DOI: 10.1186/1754-9493-3-23] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
438 Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 2021;123:911-22. [PMID: 33400838 DOI: 10.1002/jso.26367] [Reference Citation Analysis]
439 Sah BR, Owczarczyk K, Siddique M, Cook GJR, Goh V. Radiomics in esophageal and gastric cancer. Abdom Radiol (NY) 2019;44:2048-58. [PMID: 30116873 DOI: 10.1007/s00261-018-1724-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
440 de Geus-Oei LF, Vriens D, Arens AI, Hutchings M, Oyen WJ. FDG-PET/CT based response-adapted treatment. Cancer Imaging 2012;12:324-35. [PMID: 23023063 DOI: 10.1102/1470-7330.2012.9006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
441 Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther. 2008;7:986-994. [PMID: 18443433 DOI: 10.4161/cbt.7.7.6181] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
442 Rolff HC, Ambrus RB, Belmouhand M, Achiam MP, Wegmann M, Siemsen M, Kofoed SC, Svendsen LB. Robot-Assisted Hybrid Esophagectomy Is Associated with a Shorter Length of Stay Compared to Conventional Transthoracic Esophagectomy: A Retrospective Study. Minim Invasive Surg. 2017;2017:6907896. [PMID: 29362674 DOI: 10.1155/2017/6907896] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
443 Hu SB, Liu CH, Wang X, Dong YW, Zhao L, Liu HF, Cao Y, Zhong DR, Liu W, Li YL, Gao WS, Bai CM, Shang ZH, Li XY. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World J Surg Oncol 2019;17:3. [PMID: 30606195 DOI: 10.1186/s12957-018-1534-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
444 Quan R, Huang J, Chen H, Liao Y, Lv W, Chen N, Liu J, Zhang H, Xu D. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis. Oncotarget 2016;7:76316-26. [PMID: 27602756 DOI: 10.18632/oncotarget.11783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
445 Lam S, Tan E, Menezes A, Martin D, Gallagher J, Storey D, Sandroussi C. A comparison of the operative outcomes of D1 and D2 gastrectomy performed at a single Western center with multiple surgeons: a retrospective analysis with propensity score matching. World J Surg Oncol 2018;16:136. [PMID: 29986713 DOI: 10.1186/s12957-018-1422-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
446 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573 [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
447 Schoop H, Bregenzer A, Halske C, Behrens HM, Krüger S, Egberts JH, Röcken C. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort. Transl Oncol 2020;13:165-76. [PMID: 31865179 DOI: 10.1016/j.tranon.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
448 Christopherson KM, Gunther JR, Fang P, Peterson SL, Roach KE, Wong PF, Mirkovic D, Lim TY, Wang H, Wang XA, Wang C, Garcia J, Dabaja BS, Pinnix CC. Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. Clin Transl Radiat Oncol 2020;24:79-82. [PMID: 32642563 DOI: 10.1016/j.ctro.2020.05.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
449 Smyth EC. Regorafenib in gastric cancer. Transl Gastroenterol Hepatol 2017;2:16. [PMID: 28447051 DOI: 10.21037/tgh.2017.01.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
451 Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, Chang JC. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med 2012;4:291-6. [PMID: 23139717 DOI: 10.3892/etm.2012.591] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
452 Lu J, Xu BB, Shen LL, Wu D, Xue Z, Zheng HL, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH, Li P. Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer. JAMA Netw Open 2021;4:e2124760. [PMID: 34533573 DOI: 10.1001/jamanetworkopen.2021.24760] [Reference Citation Analysis]
453 Menges M. Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today? World J Gastrointest Oncol 2011; 3(1): 10-13 [PMID: 21267398 DOI: 10.4251/wjgo.v3.i1.10] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
454 Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, Schoppmann SF, Ba-Ssalamah A. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. Eur Radiol 2016;26:311-21. [PMID: 26040648 DOI: 10.1007/s00330-015-3860-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
455 Tan Y, Chen Q, Xing Y, Zhang C, Pan S, An W, Xu H. High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer. Biosci Rep 2021;41:BSR20204293. [PMID: 33739392 DOI: 10.1042/BSR20204293] [Reference Citation Analysis]
456 McCain S, Trainor J, McManus DT, McMenamin ÚC, McQuaid S, Bingham V, James JA, Salto-Tellez M, Turkington RC, Coleman HG. Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. Oncotarget 2018;9:34347-56. [PMID: 30344947 DOI: 10.18632/oncotarget.26151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
457 Mao Y, Yu Z, You B, Fang W, Badgwell B, Berry MF, Ceppa DP, Chen C, Chen H, Cuesta MA, D'Journo XB, Eslick GD, Fu J, Fu X, Gao S, He J, He J, Huang Y, Jiang G, Jiang Z, Kim JY, Li D, Li H, Li S, Liu D, Liu L, Liu Y, Li X, Li Y, Mao W, Molena D, Morse CR, Novoa NM, Tan L, Tan Q, Toker A, Tong T, Wang Q, Weksler B, Xu L, Xu S, Yan T, Zhang L, Zhang X, Zhang X, Zhang Z, Zhi X, Zhou Q. Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma. J Thorac Dis 2019;11:319-28. [PMID: 30863610 DOI: 10.21037/jtd.2018.12.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
458 Lin JX, Wang ZK, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Zheng CH, Huang CM, Li P. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Ann Surg Oncol 2021. [PMID: 33768400 DOI: 10.1245/s10434-021-09830-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
459 Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A, Segelov E. The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. Cancer Manag Res 2021;13:2567-79. [PMID: 33762848 DOI: 10.2147/CMAR.S262870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
460 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
461 Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, West NP, Wright AI, Treanor D, Hewitt LC, Allum WH, Cunningham D, Hayden JD, Grabsch HI. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget 2016;7:77565-75. [PMID: 27769054 DOI: 10.18632/oncotarget.12723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
462 Bauer K, Manzini G, Henne-Bruns D, Buechler P. Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany. World J Gastrointest Oncol 2020; 12(5): 559-568 [PMID: 32461787 DOI: 10.4251/wjgo.v12.i5.559] [Reference Citation Analysis]
463 Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng T, Liu R, Bai M, Zhou LK, Zhang XY. Change of SPARC expression after chemotherapy in gastric cancer. Cancer Biol Med. 2015;12:33-40. [PMID: 25859409 DOI: 10.7497/j.issn.2095-3941.2014.0023] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
464 Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 2020; 12(1): 37-53 [PMID: 31966912 DOI: 10.4251/wjgo.v12.i1.37] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
465 Guner A. Recent trends of gastric cancer treatment in Turkey. Transl Gastroenterol Hepatol 2017;2:31. [PMID: 28529985 DOI: 10.21037/tgh.2017.04.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
466 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
467 毛必静, 张志敏, 陈川, 王东, 王阁. HER2在胃癌靶向治疗中的作用及意义. 世界华人消化杂志 2014; 22(1): 31-38 [DOI: 10.11569/wcjd.v22.i1.31] [Reference Citation Analysis]
468 Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology 2017;108:114-21. [PMID: 28705573 DOI: 10.1016/j.urology.2017.05.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
469 Snyder RA, Penson DF, Ni S, Koyama T, Merchant NB. Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol 2014;110:285-90. [PMID: 24891231 DOI: 10.1002/jso.23635] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
470 Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, Brosens LAA, Defize IL, van Dieren JM, Dijkstra H, van Hillegersberg R, Hulshof MC, van Laarhoven HWM, Lam MGEH, van Lier ALHMW, Muijs CT, Nagengast WB, Nederveen AJ, Noordzij W, Plukker JTM, van Rossum PSN, Ruurda JP, van Sandick JW, Weusten BLAM, Voncken FEM, Yakar D, Meijer GJ; PRIDE study group. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer 2018;18:1006. [PMID: 30342494 DOI: 10.1186/s12885-018-4892-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
471 Nakamura N, Kinami S, Fujita J, Kaida D, Tomita Y, Miyata T, Fujita H, Ueda N, Takamura H. Advanced gastric cancer with abdominal wall invasion treated with curative resection after chemotherapy: a case report. J Med Case Rep 2021;15:230. [PMID: 33964982 DOI: 10.1186/s13256-021-02820-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Alt-Epping B, Alt-Epping S, Quintel M, Nauck F. [Developments in modern oncology. Ramifications for anesthesia and intensive care medicine]. Anaesthesist 2009;58:821-6. [PMID: 19452136 DOI: 10.1007/s00101-009-1561-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
473 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 243] [Article Influence: 31.1] [Reference Citation Analysis]
474 Li Z, Jia Y, Zhu H, Xing X, Pang F, Shan F, Li S, Wang D, Zhao F, Ma T, Wang S, Ji J. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer 2021;24:1342-54. [PMID: 34406546 DOI: 10.1007/s10120-021-01207-3] [Reference Citation Analysis]
475 Liu W, Quan H, Chen X, Ouyang Y, Xiao H. Clinicopathological features and prognosis of young gastric cancer patients following radical gastrectomy: a propensity score matching analysis. Sci Rep 2019;9:5943. [PMID: 30976037 DOI: 10.1038/s41598-019-42406-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
476 Nelen SD, Verhoeven RHA, Lemmens VEPP, de Wilt JHW, Bosscha K. Increasing survival gap between young and elderly gastric cancer patients. Gastric Cancer 2017;20:919-28. [PMID: 28275933 DOI: 10.1007/s10120-017-0708-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
477 Wedding U. [Chances and limitations of chemotherapy in elderly patients]. Internist (Berl) 2010;51:402, 404-6, 408-9. [PMID: 20169327 DOI: 10.1007/s00108-010-2601-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
478 Porzsolt F, Bauer K, Henne-Bruns D. [Clinical economics: a concept to optimize healthcare services]. Chirurg 2012;83:268-73. [PMID: 22406680 DOI: 10.1007/s00104-011-2200-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
479 Chen S, Chen YB, Li YF, Feng XY, Zhou ZW, Yuan XH, Qian CN. Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients. World J Gastroenterol 2012; 18(29): 3910-3916 [PMID: 22876045 DOI: 10.3748/wjg.v18.i29.3910] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
480 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
481 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
482 Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33:749-756. [PMID: 22198641 DOI: 10.1007/s13277-011-0285-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 7.0] [Reference Citation Analysis]
483 Zhou N, Qu Y, Xu C, Tang Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11:625-630. [PMID: 26893657 DOI: 10.3892/etm.2015.2920] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
484 Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, Matsubara T, Okada H, Yamamoto K. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer 2015;112:1652-5. [PMID: 25897674 DOI: 10.1038/bjc.2015.129] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
485 Dikken JL, Verheij M, Cats A, Jansen EP, Hartgrink HH, van de Velde CJ. Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer. 2011;14:396-398. [PMID: 21837457 DOI: 10.1007/s10120-011-0081-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
486 Mine S, Watanabe M, Imamura Y, Okamura A, Kurogochi T, Sano T. Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:184-90. [PMID: 27468743 DOI: 10.1007/s00268-016-3675-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
487 Fiorica F, Trovò M, Ottaiano A, Nasti G, Carandina I, Marzola M, De Paoli P, Berretta M. Can the addition of radiotherapy postoperatively increase clinical outcome of patients with gastric cancer? A systematic review of the literature and meta-analysis. Oncotarget 2018;9:10734-44. [PMID: 29535839 DOI: 10.18632/oncotarget.23754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
488 Mamidanna R, Almoudaris AM, Bottle A, Aylin P, Faiz O, Hanna GB. National outcomes and uptake of laparoscopic gastrectomy for cancer in England. Surg Endosc 2013;27:3348-58. [PMID: 23612763 DOI: 10.1007/s00464-013-2916-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
489 Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357-70. [PMID: 28163000 DOI: 10.1016/S1470-2045(17)30043-8] [Cited by in Crossref: 137] [Cited by in F6Publishing: 61] [Article Influence: 34.3] [Reference Citation Analysis]
490 Peyroteo M, Martins PC, Canotilho R, Correia AM, Baía C, Sousa A, Brito D, Videira JF, Santos LL, de Sousa A. Impact of the 8th edition of the AJCC TNM classification on gastric cancer prognosis-study of a western cohort. Ecancermedicalscience 2020;14:1124. [PMID: 33209115 DOI: 10.3332/ecancer.2020.1124] [Reference Citation Analysis]
491 Wang Y, He K, Zhou Z, Zhong Y, Li G, Lu J. A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Cancer Manag Res 2020;12:8491-6. [PMID: 32982442 DOI: 10.2147/CMAR.S267330] [Reference Citation Analysis]
492 Lordick F, Ott K, Sendler A. [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy]. Chirurg 2011;82:968-73. [PMID: 22002702 DOI: 10.1007/s00104-011-2127-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
493 Pantano F, Berti P, Guida FM, Perrone G, Vincenzi B, Amato MM, Righi D, Dell'aquila E, Graziano F, Catalano V, Caricato M, Rizzo S, Muda AO, Russo A, Tonini G, Santini D. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. J Cell Mol Med 2013;17:1415-21. [PMID: 24283947 DOI: 10.1111/jcmm.12109] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
494 Ognjenovic L, Trajkovski G, Gjoshev S, Shumkovski A, Dzambaz D, Hadzi-Manchev D, Volcevski G, Fildishevski I, Nikolova D, Petrushevska G, Janevska V, Janevski V. HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics. Open Access Maced J Med Sci 2018;6:1187-92. [PMID: 30087720 DOI: 10.3889/oamjms.2018.280] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
495 Cabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C. Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. Cancers (Basel) 2019;11:E396. [PMID: 30901876 DOI: 10.3390/cancers11030396] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
496 Bauer K, Porzsolt F, Henne-Bruns D. Can perioperative chemotherapy for advanced gastric cancer be recommended on the basis of current research? A critical analysis. J Gastric Cancer. 2014;14:39-46. [PMID: 24765536 DOI: 10.5230/jgc.2014.14.1.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
497 Nishikawa K, Aoyama T, Oba MS, Yoshikawa T, Matsuda C, Munemoto Y, Takiguchi N, Tanabe K, Nagata N, Imano M, Oshiro M, Fukushima R, Kataoka M, Morita S, Tsuburaya A, Mishima H, Kono T, Sakamoto J. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). J Cancer 2018;9:1725-30. [PMID: 29805697 DOI: 10.7150/jca.24733] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
498 Glatz T, Höppner J. Is There a Rationale for Structural Quality Assurance in Esophageal Surgery? Visc Med 2017;33:135-9. [PMID: 28560229 DOI: 10.1159/000458454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
499 Deng W, Wang QW, Zhang XT, Lu M, Li J, Li Y, Gong JF, Zhou J, Lu ZH, Shen L. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World J Gastroenterol 2014; 20(12): 3356-3363 [PMID: 24696615 DOI: 10.3748/wjg.v20.i12.3356] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
500 Conway AM, Salih Z, Papaxoinis G, Fletcher K, Weaver J, Patrao A, Noble R, Stamatopoulou S, Owen-Holt V, Mansoor W. Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. Med Oncol 2017;34:116. [PMID: 28500616 DOI: 10.1007/s12032-017-0976-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
501 Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother 2013;9:2533-42. [PMID: 23955093 DOI: 10.4161/hv.26065] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
502 Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, He YL, Chen D, Li W. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 2014;12:33. [PMID: 24495516 DOI: 10.1186/1479-5876-12-33] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
503 Huntington CR, Walsh K, Han Y, Salo J, Hill J. National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study. J Gastrointest Surg. 2016;20:154-163; discussion 163-164. [PMID: 26553265 DOI: 10.1007/s11605-015-2988-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
504 van der Horst S, de Maat MFG, van der Sluis PC, Ruurda JP, van Hillegersberg R. Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy (RAMIE) for patients with superior mediastinal lymph node metastasis. Ann Cardiothorac Surg 2019;8:218-25. [PMID: 31032205 DOI: 10.21037/acs.2019.01.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
505 Schuhmacher C, Novotny A, Meyer HJ. [Treatment of gastric cancer beyond current guideline: state of the art]. Chirurg 2013;84:310-5. [PMID: 23479274 DOI: 10.1007/s00104-012-2454-z] [Reference Citation Analysis]
506 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
507 Vošmik M, Laco J, Sirák I, Dvořák J, Lochman P, Hodek M, Malá P, Rejchrt S, Repák R, Leško M, Ferko A, Ryška A, Melichar B, Petera J. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathol Oncol Res 2018;24:373-83. [PMID: 28550507 DOI: 10.1007/s12253-017-0253-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
508 Choi AH, Nelson RA, Schoellhammer HF, Cho W, Ko M, Arrington A, Oxner CR, Fakih M, Wong J, Sentovich SM, Garcia-Aguilar J, Kim J. Accuracy of computed tomography in nodal staging of colon cancer patients. World J Gastrointest Surg 2015; 7(7): 116-122 [PMID: 26225194 DOI: 10.4240/wjgs.v7.i7.116] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
509 Strandby RB, Svendsen LB, Ambrus R, Rostved AA, Hasselby JP, Achiam MP. The Incidence of Free Peritoneal Tumor Cells before and after Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer. J Cytol 2020;37:40-5. [PMID: 31942097 DOI: 10.4103/JOC.JOC_164_18] [Reference Citation Analysis]
510 Reim D, Strobl AN, Buchner C, Schirren R, Mueller W, Luppa P, Ankerst DP, Friess H, Novotny A. Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome: A retrospective propensity score weighted analysis on 610 curatively resected gastric cancer patients. Medicine (Baltimore) 2016;95:e4322. [PMID: 27442682 DOI: 10.1097/MD.0000000000004322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
511 Stein HJ, Feith M, Siewert JR. [Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer]. Chirurg 2009;80:1019-22. [PMID: 19902287 DOI: 10.1007/s00104-009-1734-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
512 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
513 Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. [PMID: 24109590 DOI: 10.3389/fonc.2013.00262] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
514 Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: A review. Ann Surg Oncol. 2011;18:3338-3352. [PMID: 21537872 DOI: 10.1245/s10434-011-1732-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
515 Zhang S, Jin L, Liu J, Liu Y, Zhang T, Zhao Y, Yin N, Niu R, Li X, Xue D, Song S, Wang Y, Zhang H. Boosting Chemodynamic Therapy by the Synergistic Effect of Co-Catalyze and Photothermal Effect Triggered by the Second Near-Infrared Light. Nanomicro Lett 2020;12:180. [PMID: 34138182 DOI: 10.1007/s40820-020-00516-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
516 Baiocchi GL, Giacopuzzi S, Marrelli D, Bencivenga M, Morgagni P, Rosa F, Berselli M, Orsenigo E, Cananzi F, Tiberio G, Rausei S, Cozzaglio L, Degiuli M, Di Leo A, Fumagalli U, Portolani N, Rosati R, Roviello F, De Manzoni G; Italian Research Group for Gastric Cancer (GIRCG). Complications after gastrectomy for cancer: Italian perspective. Updates Surg 2017;69:285-8. [PMID: 28710718 DOI: 10.1007/s13304-017-0478-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
517 Fuchs S, Ashkenazi I. Retrospective Evaluation of Factors Affecting Lymph Node Retrieval Following Gastrectomies with Oncologic Intent. Rambam Maimonides Med J 2021;12. [PMID: 33938799 DOI: 10.5041/RMMJ.10434] [Reference Citation Analysis]
518 Turgeon MK, Lee RM, Keilson JM, Ju MR, Porembka MR, Alterio RE, Kronenfeld J, Datta J, Goel N, Wang A, Lee AY, Fernandez M, Richter H, Maker AV, Maithel SK, Russell MC. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers? J Surg Oncol 2021;124:551-9. [PMID: 34061369 DOI: 10.1002/jso.26554] [Reference Citation Analysis]
519 Amedei A, Niccolai E, D'Elios MM. T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. Clin Dev Immunol. 2011;2011:320571. [PMID: 22110523 DOI: 10.1155/2011/320571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
520 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
521 Wu X, Gao X, Xing X, Wen X, Li Z, Ji J. The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer. Ann Surg Oncol 2021;28:1407-16. [PMID: 32767226 DOI: 10.1245/s10434-020-09005-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
523 Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, Yagi T, Kiyozumi Y, Eto T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surg Today 2018;48:994-1003. [PMID: 29926189 DOI: 10.1007/s00595-018-1684-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
524 Yu JH, Wang ZZ, Fan YC, Liu MX, Xu K, Zhang N, Yao ZD, Yang H, Zhang CH, Xing JD, Cui M, Su XQ. Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis. Chin Med J (Engl) 2021;134:1669-80. [PMID: 34397593 DOI: 10.1097/CM9.0000000000001603] [Reference Citation Analysis]
525 Sun H. Identification of key genes associated with gastric cancer based on DNA microarray data. Oncol Lett 2016;11:525-30. [PMID: 26870242 DOI: 10.3892/ol.2015.3929] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
526 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
527 Turato C, Scarpa M, Kotsafti A, Cappon A, Quarta S, Biasiolo A, Cavallin F, Trevellin E, Guzzardo V, Fassan M, Chiarion-Sileni V, Castoro C, Rugge M, Vettor R, Scarpa M, Pontisso P. Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Sci 2019;110:1552-63. [PMID: 30825353 DOI: 10.1111/cas.13986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
528 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427-1433. [PMID: 26554656 DOI: 10.1038/bjc.2015.354] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
529 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
530 Hayashi T, Yoshikawa T, Sakamaki K, Nishikawa K, Fujitani K, Tanabe K, Misawa K, Matsui T, Miki A, Nemoto H, Fukunaga T, Kimura Y, Hihara J. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer. Ann Gastroenterol Surg 2020;4:540-8. [PMID: 33005849 DOI: 10.1002/ags3.12352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Choi AH, Nelson RA, Merchant SJ, Kim JY, Chao J, Kim J. Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. Gastrointest Endosc 2016;83:1184-1192.e1. [PMID: 26546980 DOI: 10.1016/j.gie.2015.10.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
532 Butt J, Kandel G. Barrett esophagus: when to endoscope. Clin Endosc 2014;47:40-6. [PMID: 24570882 DOI: 10.5946/ce.2014.47.1.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
533 Kim YW, Joo J, Yoon HM, Eom BW, Ryu KW, Choi IJ, Kook MC, Schuhmacher C, Siewert JR, Reim D. Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer: Results from a propensity score matched analysis comparing a Korean and a German specialized center. Medicine (Baltimore) 2016;95:e4261. [PMID: 27428238 DOI: 10.1097/MD.0000000000004261] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
534 Ji X, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res. 2019;47:2524-2532. [PMID: 31039658 DOI: 10.1177/0300060519845491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
535 Zhou Y, Tian M, Güngör C, Wang D. Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis. PLoS One 2021;16:e0251555. [PMID: 33979405 DOI: 10.1371/journal.pone.0251555] [Reference Citation Analysis]
536 Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 2020;20:313-27. [PMID: 33024587 DOI: 10.5230/jgc.2020.20.e29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
537 Seidlitz T, Chen YT, Uhlemann H, Schölch S, Kochall S, Merker SR, Klimova A, Hennig A, Schweitzer C, Pape K, Baretton GB, Welsch T, Aust DE, Weitz J, Koo BK, Stange DE. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations. Gastroenterology 2019;157:1599-1614.e2. [PMID: 31585123 DOI: 10.1053/j.gastro.2019.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
538 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
539 Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, Peng CW, Yang GF, Li Y. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29. [PMID: 24886548 DOI: 10.1186/1471-2482-14-29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
540 Fushida S, Nashimoto A, Fukushima N, Kawachi Y, Fujimura T, Kuwabara S, Musha N; DCS Study Group. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer. Jpn J Clin Oncol 2012;42:131-3. [PMID: 22167664 DOI: 10.1093/jjco/hyr183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
541 Groene O, Chadwick G, Riley S, Hardwick RH, Crosby T, Greenaway K, Allum W, Cromwell DA. Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges. BMC Res Notes 2014;7:24. [PMID: 24406032 DOI: 10.1186/1756-0500-7-24] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
542 Villanueva L, Anabalon J, Butte JM, Salman P, Panay S, Milla E, Gallardo C, Hoefler S, Charles R, Reyes F, Barajas O, Matamala L, Molina A, Portiño S, Berrios M, Caglevic C, Mahave M. Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety. Ecancermedicalscience 2021;15:1168. [PMID: 33680082 DOI: 10.3332/ecancer.2021.1168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
543 Gemmill EH, Humes DJ, Catton JA. Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Ann R Coll Surg Engl. 2015;97:173-179. [PMID: 26263799 DOI: 10.1308/003588414X14055925061630] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
544 Zhang X, Huang H, Wei Z, Zhu Z, Yang D, Fu H, Xu J, Hu Z, Zhang Y, You Q, Huang X, Yan R, Wang W, Cai Q. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Cancer Manag Res 2020;12:6641-53. [PMID: 32801898 DOI: 10.2147/CMAR.S258360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
545 Kung CH, Tsai JA, Lundell L, Johansson J, Nilsson M, Lindblad M. Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery. BJS Open 2020;4:424-31. [PMID: 32129948 DOI: 10.1002/bjs5.50270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
546 Tang C, Feng W, Bao Y, Chen C. Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis. Onco Targets Ther 2020;13:12661-6. [PMID: 33324076 DOI: 10.2147/OTT.S271884] [Reference Citation Analysis]
547 Kim DW, Kwon OK, Yoo MW, Ryu SW, Oh SJ, Hur H, Hwang SH, Lee J, Jin SH, Lee SE, Kim JH, Kim JJ, Jeong IH, Jee YS. Actual compliance to adjuvant chemotherapy in gastric cancer. Ann Surg Treat Res 2019;96:185-90. [PMID: 30941322 DOI: 10.4174/astr.2019.96.4.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
548 Wang X, Wei Y, Xue Y, Lu P, Yu L, Shen B. Predictive Role of the Number of 18F-FDG-Positive Lymph Nodes Detected by PET/CT for Pre-Treatment Evaluation of Locally Advanced Gastric Cancer. PLoS One 2016;11:e0166836. [PMID: 27936109 DOI: 10.1371/journal.pone.0166836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
549 Ang J, Hu L, Huang PT, Wu JX, Huang LN, Cao CH, Zheng YX, Chen L. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol 2012; 18(47): 7026-7032 [PMID: 23323004 DOI: 10.3748/wjg.v18.i47.7026] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
550 Nakamura N, Kinami S, Fujita J, Kaida D, Tomita Y, Miyata T, Miyashita T, Fujita H, Ueda N, Takamura H. Relationship between fatty liver change and nutritional status after total gastrectomy in gastric cancer patients: a retrospective study. BMC Surg 2021;21:325. [PMID: 34391390 DOI: 10.1186/s12893-021-01324-x] [Reference Citation Analysis]
551 Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J, Xu H. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526. [PMID: 23153379 DOI: 10.1186/1471-2407-12-526] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
552 Ziogas D, Baltogiannis G, Fatouros M. Continuing debate on D2 lymphadenectomy for gastric cancer. World J Surg 2008;32:2127-8. [PMID: 18563483 DOI: 10.1007/s00268-008-9645-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
553 孙姗姗, 赵爱光, 杨金坤, 赵刚, 蔡泳, 李朝燕. 健脾为基础的复方辨证治疗对胃癌根治术后无病生存期的影响. 世界华人消化杂志 2011; 19(6): 581-587 [DOI: 10.11569/wcjd.v19.i6.581] [Reference Citation Analysis]
554 Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel). 2013;5:64-91. [PMID: 24216699 DOI: 10.3390/cancers5010064] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
555 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
556 Watanabe M. Recent Topics and Perspectives on Esophageal Cancer in Japan. JMA J 2018;1:30-9. [PMID: 33748520 DOI: 10.31662/jmaj.2018-0002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
557 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
558 Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027-1040. [PMID: 26606931 DOI: 10.1007/s10120-015-0564-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
559 Yu B, Gu D, Zhang X, Li J, Liu B, Xie J. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget 2017;8:27412-27. [PMID: 28404967 DOI: 10.18632/oncotarget.16174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
560 Hoang T, Park M, Hiyama D, Dayyani F. Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience. J Gastrointest Oncol 2020;11:411-20. [PMID: 32399281 DOI: 10.21037/jgo.2019.01.08] [Reference Citation Analysis]
561 Rauh S, Mavroeidis L, Ntellas P, Gazouli I, Gkoura S, Papadaki A, Mauri D, Metaxas Y, Douillard JY, Pentheroudakis G. Old drug, new clinical use, no man's land for the indication: an awareness call from European experts. ESMO Open 2020;5:e000615. [PMID: 33551069 DOI: 10.1136/esmoopen-2019-000615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
562 Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329. [PMID: 21810227 DOI: 10.1186/1471-2047.11-329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
563 Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398:239-249. [PMID: 23269519 DOI: 10.1007/s00423-012-1039-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
564 Sasako M. Surgery and adjuvant chemotherapy. Int J Clin Oncol. 2008;13:193-195. [PMID: 18553226 DOI: 10.1007/s10147-008-0791-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
565 Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68:299-317. [PMID: 18257608 DOI: 10.2165/00003495-200868030-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
566 Griffiths EA, Gregory CJ, Pursnani KG, Ward JB, Stockwell RC. The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease. Surg Endosc. 2012;26:2367-2375. [PMID: 22395954 DOI: 10.1007/s00464-012-2192-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
567 Kaydıhan N, Çepni K, Ergen ŞA, Şenocak MŞ, Öksüz DÇ. Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Jpn J Radiol 2017;35:733-9. [PMID: 29064001 DOI: 10.1007/s11604-017-0692-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
568 Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 2011;68:863-70. [PMID: 21286719 DOI: 10.1007/s00280-011-1556-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
569 Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. Int J Radiat Oncol Biol Phys 2013;85:355-62. [PMID: 23040221 DOI: 10.1016/j.ijrobp.2012.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
570 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
571 Hernando-Cubero J, Matos-García I, Alonso-Orduña V, Capdevila J. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J Gastrointest Cancer 2017;48:135-47. [PMID: 28397102 DOI: 10.1007/s12029-017-9946-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
572 曹秀峰. 食管癌新辅助放化疗对手术及生存率的影响. 世界华人消化杂志 2010; 18(24): 2511-2514 [DOI: 10.11569/wcjd.v18.i24.2511] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
573 Dassen AE, Bernards N, Lemmens VE, Wouw YAV, Bosscha K, Creemers GJ, Pruijt HJ. Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg 2016; 8(10): 706-712 [PMID: 27830043 DOI: 10.4240/wjgs.v8.i10.706] [Reference Citation Analysis]
574 He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273 [PMID: 24415881 DOI: 10.3748/wjg.v20.i1.264] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
575 Sisic L, Vallböhmer D, Stoecklein NH, Blank S, Schmidt T, Driemel C, Möhlendick B, Knoefel WT, Odenthal M, Ott K. Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer. Oncol Lett 2015;10:869-74. [PMID: 26622585 DOI: 10.3892/ol.2015.3341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
576 Humphries MP, Craig SG, Kacprzyk R, Fisher NC, Bingham V, McQuaid S, Murray GI, McManus D, Turkington RC, James J, Salto-Tellez M. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer 2020;20:500. [PMID: 32487090 DOI: 10.1186/s12885-020-06987-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
577 Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol 2012;9:194-5. [PMID: 22392288 DOI: 10.1038/nrgastro.2012.35] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
578 Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021;28:1939-49. [PMID: 33415559 DOI: 10.1245/s10434-020-09478-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
579 Korkeila EA, Salminen T, Kallio R, Mikkola M, Auvinen P, Pyrhönen S, Ristamäki R. Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer. Support Care Cancer 2017;25:2771-7. [PMID: 28424889 DOI: 10.1007/s00520-017-3689-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
580 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
581 Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, Chen DT, Marquez DD, Hodul PJ. Does histology really influence gastric cancer prognosis? J Gastrointest Oncol 2017;8:1026-36. [PMID: 29299363 DOI: 10.21037/jgo.2017.09.08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
582 Maggen C, Lok CA, Cardonick E, van Gerwen M, Ottevanger PB, Boere IA, Koskas M, Halaska MJ, Fruscio R, Gziri MM, Witteveen PO, Van Calsteren K, Amant F; International Network on Cancer, Infertility and Pregnancy (INCIP). Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. Acta Obstet Gynecol Scand 2020;99:79-88. [PMID: 31529466 DOI: 10.1111/aogs.13731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
583 Hundahl SA. The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma. Gastric Cancer. 2012;15:3-4. [PMID: 22160297 DOI: 10.1007/s10120-011-0121-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
584 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
585 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
586 Brenkman HJ, Correa-Cote J, Ruurda JP, van Hillegersberg R. A Step-Wise Approach to Total Laparoscopic Gastrectomy with Jejunal Pouch Reconstruction: How and Why We Do It. J Gastrointest Surg. 2016;20:1908-1915. [PMID: 27561635 DOI: 10.1007/s11605-016-3235-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
587 Ni C, Yang P, Guo J, Ye M. Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer. Onco Targets Ther 2018;11:2259-67. [PMID: 29719408 DOI: 10.2147/OTT.S162253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
588 Glückstein MI, Dintner S, Arndt TT, Vlasenko D, Schenkirsch G, Agaimy A, Müller G, Märkl B, Grosser B. Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. Cancers (Basel) 2021;13:3894. [PMID: 34359794 DOI: 10.3390/cancers13153894] [Reference Citation Analysis]
589 Glatz T, Marjanovic G, Zirlik K, Brunner T, Hopt UT, Makowiec F, Hoeppner J. [Surgical treatment of esophageal cancer : Evolution of management and prognosis over the last 3 decades]. Chirurg 2015;86:662-9. [PMID: 25312491 DOI: 10.1007/s00104-014-2877-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
590 Jiang L, Ma Z, Ye X, Kang W, Yu J. Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. World J Surg Oncol 2021;19:44. [PMID: 33563277 DOI: 10.1186/s12957-021-02157-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
591 Lago NM, Villar MV, Ponte RV, Nallib IA, Alvarez JJC, López JRA, López RL, Iruegas MEP. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience 2020;14:1020. [PMID: 32256703 DOI: 10.3332/ecancer.2020.1020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
592 Deng J, Zhang Q, Lu L, Fan C. Long Noncoding RNA DLGAP1-AS1 Promotes the Aggressive Behavior of Gastric Cancer by Acting as a ceRNA for microRNA-628-5p and Raising Astrocyte Elevated Gene 1 Expression. Cancer Manag Res 2020;12:2947-60. [PMID: 32431541 DOI: 10.2147/CMAR.S246166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
593 Hensel F, Timmermann W, von Rahden BH, Rosenwald A, Brändlein S, Illert B. Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep 2014;31:1059-66. [PMID: 24452482 DOI: 10.3892/or.2014.2987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
594 Nakamura N, Kinami S, Tomita Y, Miyata T, Fujita H, Takamura H, Ueda N, Kosaka T. The neutrophil/lymphocyte ratio as a predictor of successful conversion surgery for stage IV gastric cancer: a retrospective study. BMC Cancer 2020;20:363. [PMID: 32349701 DOI: 10.1186/s12885-020-06884-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
595 Thompson RJ, Ranaghan L, Kennedy R, Clements W, Carey PD, Kennedy JA. Survival following operative management of gastric linitis plastica compared with non-operative management. Ann R Coll Surg Engl 2017;99:228-32. [PMID: 27809576 DOI: 10.1308/rcsann.2016.0337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
596 Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, Zhu Z, Li C. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med 2020;8:1684. [PMID: 33490196 DOI: 10.21037/atm-20-7802] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
597 Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, Yang HK, Kim WH, Goldenring JR. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology. 2010;139:213-25.e3. [PMID: 20398667 DOI: 10.1053/j.gastro.2010.04.008] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 8.0] [Reference Citation Analysis]
598 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis 2017;9:200-4. [PMID: 28203424 DOI: 10.21037/jtd.2017.01.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
599 Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, Harada N. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol 2015;3:987-94. [PMID: 26623038 DOI: 10.3892/mco.2015.609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
600 Ott K, Lordick F. [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg 2009;80:1028-34. [PMID: 19756431 DOI: 10.1007/s00104-009-1736-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
601 Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, Ristimäki A, Räsänen JV, Saarnio J, Sihvo E, Toikkanen V, Tyrväinen T. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open 2019;9:e024094. [PMID: 30782726 DOI: 10.1136/bmjopen-2018-024094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
602 Wang F, Gao SG, Xue Q, Tan FW, Gao YS, Wang DL, Mao YS, Zhao J, Li Y, Yu XY, Cheng H, Zhao CG, Yang D, Mu JW. Nomogram for predicting the overall survival of the patients with oesophageal signet ring cell carcinoma. J Thorac Dis 2021;13:1315-26. [PMID: 33841925 DOI: 10.21037/jtd-20-3084] [Reference Citation Analysis]
603 Morganti AG, Di Castelnuovo A, Massaccesi M, Cellini F, Cilla S, Macchia G, Forte P, Buwenge M, Digesu C, Ferro M, Picardi V, Caravatta L, Valentini V, Deodato F. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. Br J Radiol 2013;86:20130274. [PMID: 23894149 DOI: 10.1259/bjr.20130274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
604 Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 2017;8:1009-17. [PMID: 29299361 DOI: 10.21037/jgo.2017.04.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
605 Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis. World J Gastroenterol 2010; 16(44): 5621-5628 [PMID: 21105197 DOI: 10.3748/wjg.v16.i44.5621] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
606 Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020;20:886. [PMID: 32933498 DOI: 10.1186/s12885-020-07388-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
607 Chen X, Liu H, Li G, Yu J. Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next? Chin J Cancer Res 2019;31:892-900. [PMID: 31949391 DOI: 10.21147/j.issn.1000-9604.2019.06.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
608 Greer SU, Nadauld LD, Lau BT, Chen J, Wood-Bouwens C, Ford JM, Kuo CJ, Ji HP. Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Med 2017;9:57. [PMID: 28629429 DOI: 10.1186/s13073-017-0447-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
609 Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. [PMID: 29040299 DOI: 10.1371/journal.pone.0186362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
610 van den Berg I, van de Weerd S, Roodhart JML, Vink GR, van den Braak RRJC, Jimenez CR, Elias SG, van Vliet D, Koelink M, Hong E, van Grevenstein WMU, van Oijen MGH, Beets-Tan RGH, van Krieken JHJM, IJzermans JNM, Medema JP, Koopman M; CONNECTION-study group. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study. BMC Cancer 2020;20:776. [PMID: 32811457 DOI: 10.1186/s12885-020-07236-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
611 Leiting JL, Grotz TE. Advancements and challenges in treating advanced gastric cancer in the West. World J Gastrointest Oncol 2019; 11(9): 652-664 [PMID: 31558971 DOI: 10.4251/wjgo.v11.i9.652] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
612 Zhang D, Wu JR, Duan XJ, Wang KH, Zhao Y, Ni MW, Liu SY, Zhang XM, Zhang B. A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer. Front Pharmacol 2019;10:717. [PMID: 31333452 DOI: 10.3389/fphar.2019.00717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
613 Lorenzon L, Giudicissi R, Scatizzi M, Balducci G, Cantafio S, Biondi A, Persiani R, Mercantini P, D'Ugo D. D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature. BMC Surg 2020;20:126. [PMID: 32522177 DOI: 10.1186/s12893-020-00714-x] [Reference Citation Analysis]
614 Al-Attar A, Gossage L, Fareed KR, Shehata M, Mohammed M, Zaitoun AM, Soomro I, Lobo DN, Abbotts R, Chan S, Madhusudan S. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer 2010;102:704-9. [PMID: 20087352 DOI: 10.1038/sj.bjc.6605541] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
615 Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, Xu RH. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med 2013;11:277. [PMID: 24180516 DOI: 10.1186/1479-5876-11-277] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
616 Ma L, Wang X, Lan F, Yu Y, Ouyang X, Liu W, Xie F, Huang Q. Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma. Med Oncol. 2015;32:338. [PMID: 25452171 DOI: 10.1007/s12032-014-0338-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
617 Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Indian J Surg Oncol. 2011;2:16-23. [PMID: 22696066 DOI: 10.1007/s13193-011-0074-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
618 Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R; Gastroesophageal Metastasectomy Group. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 2019;32:doz034. [PMID: 31220859 DOI: 10.1093/dote/doz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
619 Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Liu FL, Zhao NQ, Liu TS. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget 2016;7:76298-307. [PMID: 27602586 DOI: 10.18632/oncotarget.11818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
620 Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget 2018;9:18518-28. [PMID: 29719622 DOI: 10.18632/oncotarget.24906] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
621 Ito K, Mitsunaga M, Arihiro S, Saruta M, Matsuoka M, Kobayashi H, Tajiri H. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer 2016;16:37. [PMID: 26810644 DOI: 10.1186/s12885-016-2072-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
622 Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010; 16(7): 868-874 [PMID: 20143466 DOI: 10.3748/wjg.v16.i7.868] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
623 Wang Z, Ji F. Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol Lett. 2018;15:4585-4591. [PMID: 29541229 DOI: 10.3892/ol.2018.7822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
624 Arora N, Alsaied O, Dauer P, Majumder K, Modi S, Giri B, Dudeja V, Banerjee S, Von Hoff D, Saluja A. Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer. PLoS One. 2017;12:e0171827. [PMID: 28192510 DOI: 10.1371/journal.pone.0171827] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
625 Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ 2021;43:21. [PMID: 34099061 DOI: 10.1186/s41021-021-00192-4] [Reference Citation Analysis]
626 Schernberg A, Moureau-Zabotto L, Rivin Del Campo E, Escande A, Ducreux M, Nguyen F, Goere D, Chargari C, Deutsch E. Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget 2017;8:11579-88. [PMID: 28086222 DOI: 10.18632/oncotarget.14584] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
627 Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-8. [PMID: 18349821 DOI: 10.1038/sj.bjc.6604251] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
628 Schernberg A, Rivin Del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018;10:13-22. [PMID: 29928701 DOI: 10.1016/j.ctro.2018.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
629 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 104] [Article Influence: 51.5] [Reference Citation Analysis]
630 Zhao C, Feng Z, He H, Zang D, Du H, Huang H, Du Y, He J, Zhou Y, Nie Y. Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray. PLoS One 2020;15:e0238836. [PMID: 33095797 DOI: 10.1371/journal.pone.0238836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
631 Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg 2016;20:172-9; discussion 179. [PMID: 26394879 DOI: 10.1007/s11605-015-2954-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
632 Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X, Hu S. Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer. Mol Clin Oncol 2014;2:93-8. [PMID: 24649314 DOI: 10.3892/mco.2013.191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
633 Liu X, Jin J, Cai H, Huang H, Zhao G, Zhou Y, Wu J, Du C, Long Z, Fang Y, Ma M, Li G, Zhou M, Yin J, Zhu X, Zhu J, Sheng W, Huang D, Zhu H, Zhang Z, Lu Q, Xie L, Zhang Z, Wang Y. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 2019;19:606. [PMID: 31221115 DOI: 10.1186/s12885-019-5728-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
634 Sakin A, Sahin S, Sakin A, Aldemir MN, Bayram I, Kotan C. The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Asian Pac J Cancer Prev 2020;21:2723-31. [PMID: 32986374 DOI: 10.31557/APJCP.2020.21.9.2723] [Reference Citation Analysis]
635 Morgant S, Artru P, Oudjit A, Lourenco N, Pasquer A, Walter T, Gornet JM, Rouquette A, Brezault C, Coriat R. Endoscopic ultrasound efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study. Ann Transl Med 2021;9:50. [PMID: 33553343 DOI: 10.21037/atm-20-3474] [Reference Citation Analysis]
636 Venerito M. S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. Drugs R D 2019;19:141-8. [PMID: 30825156 DOI: 10.1007/s40268-019-0265-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
637 Zhao H, Xiao H, Lu Y, Liu S, Wang C. Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539. Cell Cycle 2020;19:1143-57. [PMID: 32308105 DOI: 10.1080/15384101.2020.1749404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
638 Chen X, Eads JR, Ammori JB, Kumar AM, Biswas T, Dorth JA. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? Curr Oncol Rep 2015;17:18. [PMID: 25708803 DOI: 10.1007/s11912-015-0442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
639 Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS One 2013;8:e53149. [PMID: 23359796 DOI: 10.1371/journal.pone.0053149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
640 Ahmed SMU, Jiang ZN, Zheng ZH, Li Y, Wang XJ, Tang X. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett 2019;17:773-80. [PMID: 30655829 DOI: 10.3892/ol.2018.9705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
641 Mohri Y, Tanaka K, Toiyama Y, Ohi M, Yasuda H, Inoue Y, Kusunoki M. Impact of Preoperative Neutrophil to Lymphocyte Ratio and Postoperative Infectious Complications on Survival After Curative Gastrectomy for Gastric Cancer: A Single Institutional Cohort Study. Medicine (Baltimore). 2016;95:e3125. [PMID: 26986164 DOI: 10.1097/md.0000000000003125] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 8.2] [Reference Citation Analysis]
642 Ao T, Kajiwara Y, Yamada K, Shinto E, Mochizuki S, Okamoto K, Yamadera M, Yonemura K, Ueno H. Cancer-induced spiculation on computed tomography: a significant preoperative prognostic factor for colorectal cancer. Surg Today 2019;49:629-36. [PMID: 30790053 DOI: 10.1007/s00595-019-01780-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Vining CC, Skowron KB, Hogg ME. Robotic gastrointestinal surgery: learning curve, educational programs and outcomes. Updates Surg 2021;73:799-814. [PMID: 33484423 DOI: 10.1007/s13304-021-00973-0] [Reference Citation Analysis]
644 Zhang D, Qian C, Wei H, Qian X. Identification of the Prognostic Value of Tumor Microenvironment-Related Genes in Esophageal Squamous Cell Carcinoma. Front Mol Biosci 2020;7:599475. [PMID: 33381521 DOI: 10.3389/fmolb.2020.599475] [Reference Citation Analysis]
645 Liu S, Wu M, Peng M. Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p. Cancer Manag Res 2020;12:10505-19. [PMID: 33122949 DOI: 10.2147/CMAR.S272324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
646 Park CJ, Seo N, Hyung WJ, Koom WS, Kim HS, Kim MJ, Lim JS. Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy. PLoS One 2018;13:e0202207. [PMID: 30092078 DOI: 10.1371/journal.pone.0202207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
647 Choi JH, Suh YS, Choi Y, Han J, Kim TH, Park SH, Kong SH, Lee HJ, Yang HK. Comprehensive Analysis of the Neutrophil-to-Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer. World J Surg. 2018;42:2530-2541. [PMID: 29392430 DOI: 10.1007/s00268-018-4510-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
648 Fencl P, Belohlavek O, Harustiak T, Zemanova M. FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction. Abdom Radiol (NY) 2016;41:2089-94. [PMID: 27405645 DOI: 10.1007/s00261-016-0820-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
649 Kinoshita O, Ichikawa D, Ichijo Y, Komatsu S, Okamoto K, Kishimoto M, Yanagisawa A, Otsuji E. Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. World J Gastroenterol 2015; 21(48): 13500-13506 [PMID: 26730161 DOI: 10.3748/wjg.v21.i48.13500] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
650 Ekheden I, Ebrahim F, Ólafsdóttir H, Raaschou P, Wettermark B, Henriksson R, Ye W. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort. Eur J Clin Pharmacol 2020;76:1029-41. [PMID: 32372150 DOI: 10.1007/s00228-020-02883-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
651 Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer. 2014;14:183. [PMID: 24628950 DOI: 10.1186/1471-2407-14-183] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 13.6] [Reference Citation Analysis]
652 Mahar AL, El-Sedfy A, Brar SS, Johnson A, Coburn N. Are we lacking economic evaluations in gastric cancer treatment? Pharmacoeconomics 2015;33:83-7. [PMID: 25192732 DOI: 10.1007/s40273-014-0215-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
653 Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh CS. Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Ann Gastroenterol Surg 2019;3:592-7. [PMID: 31788647 DOI: 10.1002/ags3.12301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
654 Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, Dong F, Gao W, Bai C, Li X. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer 2016;114:1326-33. [PMID: 27172250 DOI: 10.1038/bjc.2016.126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
655 Saito H, Murakami Y, Miyatani K, Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ikeguchi M. Predictive factors for recurrence in T2N0 and T3N0 gastric cancer patients. Langenbecks Arch Surg 2016;401:823-8. [PMID: 27460840 DOI: 10.1007/s00423-016-1480-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
656 Yin X, Fang T, Wang Y, Li C, Wang Y, Zhang D, Xue Y. Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet-Lymphocyte Ratio in Patients Receiving XELOX. Front Oncol 2020;10:584772. [PMID: 33425738 DOI: 10.3389/fonc.2020.584772] [Reference Citation Analysis]
657 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015; 21(47): 13294-13301 [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
658 Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol 2018;117:1721-8. [PMID: 29949666 DOI: 10.1002/jso.25081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
659 Paireder M, Jomrich G, Asari R, Kristo I, Gleiss A, Preusser M, Schoppmann SF. External validation of the NUn score for predicting anastomotic leakage after oesophageal resection. Sci Rep 2017;7:9725. [PMID: 28852063 DOI: 10.1038/s41598-017-10084-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
660 Guo X, Wang Y, Zhang H, Qin C, Cheng A, Liu J, Dai X, Wang Z. Identification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer. Front Genet 2020;11:989. [PMID: 32973887 DOI: 10.3389/fgene.2020.00989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
661 Yashiro M, Inoue T, Nishioka N, Matsuoka T, Boland CR, Hirakawa K. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol. 2009;16:2926-2935. [PMID: 19597886 DOI: 10.1245/s10434-009-0590-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
662 Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Med. 2017;6:361-373. [PMID: 28074552 DOI: 10.1002/cam4.989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
663 He Q, Li Y, Ma L, Ji X, Li G. Application of FLEEOX Preoperative Chemotherapy via Intra-arterial and Intravenous Administration in Treatment of Unresectable Locally Advanced Gastric Cancer. J Gastrointest Surg 2016;20:1421-7. [PMID: 27114248 DOI: 10.1007/s11605-016-3153-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
664 Ruf C, Thomusch O, Goos M, Makowiec F, Illerhaus G, Ruf G. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma. BMC Surg. 2014;14:5. [PMID: 24461063 DOI: 10.1186/1471-2482-14-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
665 Zaydfudim VM, Vachharajani N, Klintmalm GB, Jarnagin WR, Hemming AW, Doyle MB, Cavaness KM, Chapman WC, Nagorney DM. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016;264:650-8. [PMID: 27433910 DOI: